var title_f37_47_38640="Scopolamine: Patient drug information";
var content_f37_47_38640=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Scopolamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/8/4228?source=see_link\">",
"       Scopolamine (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/12/10437?source=see_link\">",
"       Scopolamine (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11860 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38640=[""].join("\n");
var outline_f37_47_38640=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/8/4228?source=related_link\">",
"      Scopolamine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/12/10437?source=related_link\">",
"      Scopolamine (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_47_38641="Patient information: Learning disabilities (The Basics)";
var content_f37_47_38641=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/18/24865\">",
"         Patient information: Asperger syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/32/11778\">",
"         Patient information: Attention deficit hyperactivity disorder (ADHD) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/37/38481\">",
"         Patient information: Autism (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/22/29025\">",
"         Patient information: Dyslexia (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/46/41699\">",
"         Patient information: Autism spectrum disorders (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/8/33922\">",
"         Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Learning disabilities (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1833309773\">",
"      <span class=\"h1\">",
"       What are learning disabilities?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Learning disabilities are problems that cause a child to have trouble learning. For example, a child might have problems learning read, write, or do math. Learning disabilities do not have anything to do with how smart a child is. Children with learning disabilities can be just as smart or smarter than other children their age. But they have brain differences that make it hard for them to learn, remember, and use information.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1833309788\">",
"      <span class=\"h1\">",
"       What are the symptoms of learning disabilities?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is not being able to learn as well as other children. For example, a child with a learning disability might not be able to read, write, or do math as well as other children who are the same age or in the same grade.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1833309803\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your child will likely have a number of different tests. The tests check for any problems in the following areas:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        IQ &ndash; IQ stands for &ldquo;intelligence quotient.&rdquo; This test measures how well a person solves problems and understands things.",
"       </li>",
"       <li>",
"        Vision",
"       </li>",
"       <li>",
"        Hearing",
"       </li>",
"       <li>",
"        Speech",
"       </li>",
"       <li>",
"        Motor skills &ndash; These tests check how well a child can move large muscles (such as in the legs and arms) and small muscles (such as in the fingers).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The tests also include a review of the child&rsquo;s school records and watching how he or she acts in a classroom. Different experts, including special education teachers, social workers, or guidance counselors, can do these tests.",
"     </p>",
"     <p>",
"      A doctor, nurse, or other expert might also test your child for health or emotional problems, such as worrying or feeling sad or depressed. Problems in those areas can affect how well a child can learn.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1833309820\">",
"      <span class=\"h1\">",
"       How are learning disabilities treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Learning disabilities are treated with &ldquo;special education.&rdquo; This is when a child learns from a teacher with special training. Special education uses different ways to teach children with disabilities. The methods depend on the learning disability. Examples include using pictures along with written or spoken words to explain things. Teachers might also give the child tips on how to remember things or help them stay organized. Children with learning disabilities might be given extra time to solve problems or take tests.",
"     </p>",
"     <p>",
"      The earlier your child gets tested and treated for learning disabilities, the better he or she will do in school in the future.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1833309835\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/32/11778?source=see_link\">",
"       Patient information: Attention deficit hyperactivity disorder (ADHD) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/18/24865?source=see_link\">",
"       Patient information: Asperger syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/37/38481?source=see_link\">",
"       Patient information: Autism (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/22/29025?source=see_link\">",
"       Patient information: Dyslexia (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/8/33922?source=see_link\">",
"       Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/46/41699?source=see_link\">",
"       Patient information: Autism spectrum disorders (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/47/38641?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86019 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38641=[""].join("\n");
var outline_f37_47_38641=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1833309773\">",
"      What are learning disabilities?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1833309788\">",
"      What are the symptoms of learning disabilities?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1833309803\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1833309820\">",
"      How are learning disabilities treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1833309835\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/18/24865?source=related_link\">",
"      Patient information: Asperger syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/32/11778?source=related_link\">",
"      Patient information: Attention deficit hyperactivity disorder (ADHD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/37/38481?source=related_link\">",
"      Patient information: Autism (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/46/41699?source=related_link\">",
"      Patient information: Autism spectrum disorders (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/22/29025?source=related_link\">",
"      Patient information: Dyslexia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/8/33922?source=related_link\">",
"      Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_47_38642="Patient information: Elbow tendinopathy (tennis and golf elbow) (The Basics)";
var content_f37_47_38642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16310\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/38/30319\">",
"         Forearm extensor stretch",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/32/2563\">",
"         Patient information: Biceps tendinopathy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/53/29522\">",
"         Patient information: Rotator cuff injury (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/36/25153\">",
"         Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/18/44321\">",
"         Patient information: Elbow tendinopathy (tennis and golf elbow) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/49/24341\">",
"         Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Elbow tendinopathy (tennis and golf elbow) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/elbow-tendinopathy-tennis-and-golf-elbow-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H22903287\">",
"      <span class=\"h1\">",
"       What is elbow tendinopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Elbow tendinopathy is a condition that causes elbow pain and forearm weakness. Doctors use the term &ldquo;elbow tendinopathy&rdquo; when people have a problem with a tendon in the elbow. Tendons are strong bands of tissue that connect muscles to bones. Depending on which elbow tendon is injured, the condition is also known as &ldquo;tennis elbow&rdquo; or &ldquo;golf elbow.&rdquo;",
"     </p>",
"     <p>",
"      In most people with elbow tendinopathy, the tendons are not inflamed or swollen. If they do get inflamed or swollen, doctors call it &ldquo;tendinitis.&rdquo;",
"     </p>",
"     <p>",
"      Tendinitis usually starts suddenly. Tendinopathy usually happens over a longer period of time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22903294\">",
"      <span class=\"h1\">",
"       What causes elbow tendinopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;This condition can happen as people get older, especially if they do a lot of work or activity using their elbow and forearm. Tendinitis can happen when people get hurt or do the same movements over and over.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22903301\">",
"      <span class=\"h1\">",
"       What are the symptoms of elbow tendinopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Elbow pain &mdash; The pain can start slowly or suddenly. It can spread to the upper arm or forearm.",
"       </li>",
"       <li>",
"        Weakness of the forearm muscles",
"       </li>",
"       <li>",
"        Swelling (if people have tendinitis)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22903308\">",
"      <span class=\"h1\">",
"       Is there a test for elbow tendinopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. But your doctor or nurse should be able to tell if you have it by talking with you and doing an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22903315\">",
"      <span class=\"h1\">",
"       How is elbow tendinopathy treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most of the time, this condition will get better on its own, but it can take months to heal completely. To help get better, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rest your elbow and arm &mdash; Ask your doctor about wearing an arm brace.",
"       </li>",
"       <li>",
"        Take a pain-relieving medicine &mdash; Your doctor might recommend that you take a medicine such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol&reg;),",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;), or",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22903322\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can do different exercises to help with your symptoms. The right exercises for you will depend on which elbow tendon is injured. The following exercises can help stretch the lower arm muscles:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Tennis elbow stretch &mdash; Hold your injured arm straight out, and point your fingers down to the ground. Use your other hand (with the thumb pressing on the palm) to grab this hand. Then press down on the back of the hand to bend the wrist more (",
"        <a class=\"graphic graphic_picture graphicRef65485 \" href=\"mobipreview.htm?29/38/30319\">",
"         picture 1",
"        </a>",
"        ). Hold this position for 30 seconds. Repeat the stretch 3 times. Do this exercise 1 time a day.",
"       </li>",
"       <li>",
"        Golf elbow stretch &mdash; Stand an arm&rsquo;s length away from the wall, with the injured arm closest to the wall. Put your palm on the wall, with your fingers pointing down. Press gently against the wall to stretch your muscles. Hold this position for 30 seconds. Repeat the stretch 3 times. Do this exercise 1 time a day.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other types of exercises can help make the forearm muscles stronger. Your doctor, nurse, or physical therapist (exercise expert) can show you how to do these types of exercises. He or she will tell you when to start them and how often to do them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22903329\">",
"      <span class=\"h1\">",
"       What if my symptoms don&rsquo;t get better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your symptoms don&rsquo;t get better, talk with your doctor or nurse. He or she can suggest other treatments, such as physical therapy or a shot of medicine in the tendon.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22903336\">",
"      <span class=\"h1\">",
"       Can elbow tendinopathy be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help prevent elbow tendinopathy, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Take breaks when you do activities in which you move your elbow and wrist a lot.",
"       </li>",
"       <li>",
"        Keep your elbows slightly bent when you exercise or lift things.",
"       </li>",
"       <li>",
"        Wear gloves or use 2 hands when using tools.",
"       </li>",
"       <li>",
"        Use a 2-handed backhand swing in tennis.",
"       </li>",
"       <li>",
"        Use grip tape or padding on your golf clubs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H22903343\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/32/2563?source=see_link\">",
"       Patient information: Biceps tendinopathy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/53/29522?source=see_link\">",
"       Patient information: Rotator cuff injury (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/18/44321?source=see_link\">",
"       Patient information: Elbow tendinopathy (tennis and golf elbow) (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/36/25153?source=see_link\">",
"       Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/49/24341?source=see_link\">",
"       Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/47/38642?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16310 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-92133E1D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38642=[""].join("\n");
var outline_f37_47_38642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22903287\">",
"      What is elbow tendinopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22903294\">",
"      What causes elbow tendinopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22903301\">",
"      What are the symptoms of elbow tendinopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22903308\">",
"      Is there a test for elbow tendinopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22903315\">",
"      How is elbow tendinopathy treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22903322\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22903329\">",
"      What if my symptoms don&rsquo;t get better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22903336\">",
"      Can elbow tendinopathy be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22903343\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16310\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/38/30319\">",
"      Forearm extensor stretch",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/36/25153?source=related_link\">",
"      Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/32/2563?source=related_link\">",
"      Patient information: Biceps tendinopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/18/44321?source=related_link\">",
"      Patient information: Elbow tendinopathy (tennis and golf elbow) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/53/29522?source=related_link\">",
"      Patient information: Rotator cuff injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/49/24341?source=related_link\">",
"      Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_47_38643="Cirrhosis trichrome Light";
var content_f37_47_38643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cirrhosis on needle biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Needle biopsy of the liver (40x) of a 61-year-old female with obesity, diabetes, and hyperlipidemia referred for evaluation of chronically elevated serum aminotransferases. Trichrome stain demonstrates bridging fibrosis (blue staining), peri-portal inflammatory infiltrates and marked steatosis. These findings are consistent with cirrhosis secondary to NASH.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeremy Ditelberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38643=[""].join("\n");
var outline_f37_47_38643=null;
var title_f37_47_38644="Difference in the angle of the eustachian tube";
var content_f37_47_38644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Difference in the angle of the eustachian tube in the infant and the adult",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 617px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Infants and young children have shorter, more horizontal tubes, immature floppy elastic cartilage, and larger adenoids compared to adults, which place them at a higher risk for eustachian tube obstruction and reflux.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38644=[""].join("\n");
var outline_f37_47_38644=null;
var title_f37_47_38645="Bronchoscopic laser resection";
var content_f37_47_38645=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bronchoscopic laser resection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/47/38645/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38645/contributors\">",
"     Henri G Colt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/47/38645/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38645/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/47/38645/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38645/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/47/38645/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopic laser resection is used to relieve airway obstruction. Its indications, equipment, technique, and outcomes are reviewed here. Other bronchoscopic techniques used to manage airway obstruction are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11447?source=see_link\">",
"     \"Endobronchial electrocautery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37749?source=see_link\">",
"     \"Photodynamic therapy of lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24468?source=see_link\">",
"     \"Argon plasma coagulation in the management of airway disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38292?source=see_link\">",
"     \"Bronchoscopic cryosurgery: Indications, contraindications, and outcomes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34823?source=see_link\">",
"     \"Airway stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27126?source=see_link\">",
"     \"Flexible bronchoscopy balloon dilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32038?source=see_link\">",
"     \"Endobronchial brachytherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopic laser resection can relieve malignant or benign intraluminal airway obstruction, particularly exophytic proximal airway lesions, but it has little or no role when the obstruction is caused by extrinsic compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant disease &ndash; Airway obstruction from bronchogenic carcinoma is the most frequent indication for laser resection. It is typically employed in patients who have exhausted their therapeutic options, although some may be eligible for salvage chemotherapy, brachytherapy, or surgical resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]. Other malignant causes of central airway obstruction that have been managed by laser resection include adenoid cystic carcinoma, mucoepidermoid carcinoma, and endobronchial metastases from melanoma, colon, kidney, and breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Benign disease &ndash; Airway obstruction due to a benign lesion may also be amenable to laser resection. Such lesions include benign tumors; inhaled foreign bodies; stenoses due to granulation tissue, intubation injuries, post-radiation strictures, lung transplantation, tracheal or bronchial resection and reanastomosis, or web-like strictures from inhalation injury; fibrous bands following an infection with Corynebacterium diphtheriae, Klebsiella rhinoscleromatis, tuberculosis, or fungus; or benign exophytic disease with either mucosal infiltration or circumferential narrowing due to granulomatosis with polyangiitis (formerly called Wegener's granulomatosis), tuberculosis, or endometriosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients who have benign airway strictures due to causes other than infection should always be considered for open surgical resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. Candidates for bronchoscopic laser resection include those who are not candidates for open resection because of age, overall medical status, fear of surgery, severity of other underlying disease, or the extent, location, and degree of the stricture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laser resection can be easily and safely combined with other methods of bronchoscopic treatment, including electrosurgery, cryotherapy, stenting, dilation, and brachytherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11447?source=see_link\">",
"     \"Endobronchial electrocautery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38292?source=see_link\">",
"     \"Bronchoscopic cryosurgery: Indications, contraindications, and outcomes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34823?source=see_link\">",
"     \"Airway stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27126?source=see_link\">",
"     \"Flexible bronchoscopy balloon dilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32038?source=see_link\">",
"     \"Endobronchial brachytherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9788373\">",
"    <span class=\"h2\">",
"     Principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many types of biomedical lasers, including the neodymium-yttrium-aluminum-garnet (Nd:YAG) laser, neodymium-yttrium-aluminum-perovskite (Nd:YAP) laser, carbon dioxide laser, argon ion laser, excimer laser, potassium titanyl phosphate (KTP) laser, alexandrite laser, semiconductor lasers, and pulse dye lasers. These lasers are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32151?source=see_link\">",
"     \"Basic principles of medical lasers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The laser that is most commonly used for bronchoscopic laser resection is the neodymium-yttrium-aluminum-garnet (Nd:YAG) laser. Its energy is delivered through flexible fibers that are inserted through either a rigid or flexible bronchoscope. The wavelength of this laser (1064 nm) is invisible; thus, a red helium-neon beam is used to indicate where the laser energy will be applied.",
"   </p>",
"   <p>",
"    An Nd:YAG laser can remove an obstructing airway lesion in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resection (",
"      <a class=\"graphic graphic_movie graphicRef65910 \" href=\"mobipreview.htm?5/29/5598\">",
"       movie 1",
"      </a>",
"      ) &ndash; Resection involves directing the laser at the target lesion, devitalizing the lesion via photocoagulation of the feeding blood vessels, and then extracting the devitalized tissue through the bronchoscope. This is possible because the laser penetrates tissue to a depth of up to 10 mm in an inverted cone fashion and provides reliable photocoagulation at this depth. Its power density can be altered by moving the laser closer to or farther from the target tissue.",
"     </li>",
"     <li>",
"      Vaporization (",
"      <a class=\"graphic graphic_movie graphicRef73638 \" href=\"mobipreview.htm?1/43/1727\">",
"       movie 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef80129 \" href=\"mobipreview.htm?19/56/20367\">",
"       movie 3",
"      </a>",
"      ) &ndash; Vaporization involves aligning the laser parallel to the bronchial wall and aiming at the edge of the intraluminal lesion (the laser should never be discharged perpendicular to the airway wall because of an increased risk of perforation). Laser pulses of one second or less are used to vaporize the tissue. This is possible because the energy from the laser is relatively well absorbed by water. Vaporization requires higher power densities and more tissue heat than resection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dark tissues (eg, charred or hemorrhagic tissue) and large lesions require special consideration. With respect to dark tissues, resection should be avoided because the dark color enhances tissue absorption, limits deep tissue penetration, and reduces deep photocoagulation, leading to poor devitalization of the target lesion. With respect to large lesions, vaporization should be avoided because it is time consuming and requires high tissue heat, which may cause fire and perforation.",
"   </p>",
"   <p>",
"    The major disadvantage of the Nd:YAG laser is the operator's inability to predict the extent of deep tissue damage based upon the surface appearance. If the power density increases at a sufficient depth below the surface of the target tissue, the temperature can increase above the boiling point of water. Explosion of a pocket of steam causes a \"popcorn effect\", which may result in tissue perforation, rupture, and hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9788450\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in bronchoscopic laser resection is deciding whether the procedure will be performed via rigid or flexible bronchoscopy. The former is performed in the operating room with general anesthesia, whereas the latter is generally performed in a specially equipped bronchoscopy suite with topical anesthesia and procedural sedation (ie, conscious sedation). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of rigid versus flexible bronchoscopy depends upon the bronchoscopist&rsquo;s experience and preference, as well as whether vaporization or resection of the lesion is planned. Vaporization can be performed with either rigid or flexible bronchoscopy. However, resection is generally performed with rigid bronchoscopy because the devitalized tissue can be more easily removed (ie, during rigid bronchoscopy, tissue can be easily removed with the beveled edge of the bronchoscope, forceps, or suction; with flexible bronchoscopy, tissue is difficult to remove unless the operator is particularly proficient with forceps) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/3\">",
"     3",
"    </a>",
"    ]. Like most bronchoscopists, we prefer rigid bronchoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/12\">",
"     12",
"    </a>",
"    ], although we will occasionally use flexible bronchoscopy if the airway abnormality is within a distal segmental bronchus. When we use a rigid bronchoscope, we keep a flexible bronchoscope available to remove blood and debris from the distal airways. This may require abundant saline lavage.",
"   </p>",
"   <p>",
"    After it has been determined whether the procedure will be performed via rigid or flexible bronchoscopy, appropriate personnel need to be recruited. Most laser resection teams are comprised of a bronchoscopist, an anesthesiologist experienced with interventional pulmonology techniques and airway management, an endoscopy nurse familiar with the equipment, and a second endoscopy nurse who assists the bronchoscopist and controls the laser settings. For bronchoscopy performed in the operating room, it is also helpful to have a circulating nurse available in case of complications, since both endoscopy nurses will usually be occupied assisting the bronchoscopist.",
"   </p>",
"   <p>",
"    When procedures are performed using general anesthesia, the patient&rsquo;s oxygenation and ventilation are supported throughout the procedure by spontaneous-assisted ventilation, jet ventilation, or laryngeal mask assisted ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Muscle relaxants and paralytic agents can occasionally be helpful during general anesthesia because they prevent the patient from &ldquo;bucking the vent&rdquo; or coughing during resection and they facilitate insertion of the rigid bronchoscope. However, such agents should be used sparingly and only after careful consideration of the potential risks and benefits for the following reasons. Muscle relaxants and paralytic agents allow the airways to narrow when the rib cage relaxes and this can cause airway obstruction, increase the amount of ventilator support that is required during the procedure, and increase the risk of complications if intubation fails because the patient is unable to breathe spontaneously.",
"   </p>",
"   <p>",
"    Bronchoscopic laser resection should only be performed by bronchoscopists who have advanced training and experience. Bronchoscopists and team members should remain familiar with techniques, potential complications, and necessary precautions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/16\">",
"     16",
"    </a>",
"    ]. Precautions during laser resection include wearing protective goggles, protecting the patient's eyes with saline-soaked pads and aluminum foil to avoid injury from accidental laser scatter, and minimizing the risk of combustion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The fraction of inspired oxygen should be kept below 40 percent during laser firing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Flammable materials should be kept far away from the operating field",
"     </li>",
"     <li>",
"      Silicone stents should be removed prior to laser firing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The laser should always be placed on standby mode while tissue is removed from the bronchoscope",
"     </li>",
"     <li>",
"      Adequate suction must be available to remove the combustible laser plume (the smoke caused by vaporization of tissues) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Power settings should not exceed the maximum recommended for the laser being used (eg, 40 watts for the Nd:YAG laser)",
"     </li>",
"     <li>",
"      If a flexible bronchoscope is employed, the laser must be kept a sufficient distance beyond the tip of the bronchoscope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Video systems allow all personnel to observe the procedure, which makes it easier for assistants to anticipate the needs of the bronchoscopist and the patient. Many bronchoscopic laser resection procedures are performed in less than one hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5264479\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of bronchoscopic laser resection are infrequent but they include hemorrhage, airway wall perforation, airway wall necrosis, and fistula formation. Arterial air embolism rarely complicates bronchoscopic laser resection, but may cause myocardial ischemia or a cerebrovascular accident. Studies of laser procedures performed during continuous transesophageal echocardiographic monitoring suggest that air emboli may be caused by coolant gas (which exits the bronchoscope under high flow and pressure conditions to cool the laser probe) entering the pulmonary venules and gaining access to the systemic circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/20\">",
"     20",
"    </a>",
"    ]. The frequency of this complication may be reduced by maintaining the laser fiber coolant airflow at the minimum level and avoiding direct contact between the laser probe and tissue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcome data regarding bronchoscopic laser resection are sparse. However, it appears to be a rapid and safe method to relieve airway obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/1,21\">",
"     1,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case series that included 2610 laser resections in 1838 patients with malignant airway obstruction found that airway patency improved and symptoms were palliated in over 90 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/12\">",
"     12",
"    </a>",
"    ]. The median time between a first and second palliative treatment was 102 days. Mortality was less than 1 percent within seven days of the procedure. Smaller series have reported similar results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/22-25\">",
"     22-25",
"    </a>",
"    ], while a larger series reported that death occurred in only 15 out of 5049 patients (0.3 percent) and serious complications occurred in only 119 out of 5049 patients (2.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Emergency laser resection can favorably affect healthcare utilization. Rapid patient improvement is frequently observed and may allow weaning from mechanical ventilation and transfer to a lower level of care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38645/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9787408\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchoscopic laser resection is used to relieve malignant or benign intraluminal airway obstruction. It has little or no role when the obstruction is caused by extrinsic compression. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The type of laser that is most commonly used for bronchoscopic laser resection is the neodymium-yttrium-aluminum-garnet (Nd:YAG) laser. It relieves airway obstruction by either resecting or vaporizing the obstructing lesion. (See",
"      <a class=\"local\" href=\"#H9788373\">",
"       'Principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial step in bronchoscopic laser resection is deciding whether the procedure will be performed via rigid or flexible bronchoscopy. The former is performed in the operating room with general anesthesia, whereas the latter is generally performed in a specially equipped bronchoscopy suite with topical anesthesia and procedural sedation (ie, conscious sedation). Vaporization can be performed with either rigid or flexible bronchoscopy, but resection is generally performed with rigid bronchoscopy. (See",
"      <a class=\"local\" href=\"#H9788450\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchoscopic laser resection should only be performed by bronchoscopists who have advanced training and experience. Laser teams generally consist of the bronchoscopist, an anesthesiologist, and two endoscopy nurses. For procedures performed in the operating room, it is also helpful to have a circulating nurse available. Many procedures are performed in less than one hour. (See",
"      <a class=\"local\" href=\"#H9788450\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchoscopic laser resection appears to be a rapid and safe method to relieve airway obstruction Complications are infrequent but they include hemorrhage, airway wall perforation, airway wall necrosis, fistula formation, and air embolism. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Outcomes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5264479\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/1\">",
"      Kvale PA, Selecky PA, Prakash UB, American College of Chest Physicians. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:368S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/2\">",
"      Wahidi MM, Herth FJ, Ernst A. State of the art: interventional pulmonology. Chest 2007; 131:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/3\">",
"      Ernst A, Silvestri GA, Johnstone D, American College of Chest Physicians. Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest 2003; 123:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/4\">",
"      Bolliger CT, Mathur PN, Beamis JF, et al. ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. Eur Respir J 2002; 19:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/5\">",
"      Daddi G, Puma F, Avenia N, et al. Resection with curative intent after endoscopic treatment of airway obstruction. Ann Thorac Surg 1998; 65:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/6\">",
"      Mehta AC, Golish JA, Ahmad M, et al. Palliative treatment of malignant airway obstruction by Nd-YAG laser. Cleve Clin Q 1985; 52:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/7\">",
"      Carlin, BW, Harrell, JH, Olsen, LK, Moser, KM. Endobronchial metastases due to colorectal carcinoma. Chest 1989; 96:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/8\">",
"      Puma F, Carloni A, Casucci G, et al. Successful endoscopic Nd-YAG laser treatment of endobronchial endometriosis. Chest 2003; 124:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/9\">",
"      Colt, HG, Gumbert, BC, Harrell, JH. Tracheobronchial obstruction by Klebsiella Rhinoscleroma: Diagnosis, pathologic features, and treatment. J Bronchol 1994; 1:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/10\">",
"      Colt HG. Laser bronchoscopy. Chest Surg Clin N Am 1996; 6:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/11\">",
"      Fisher JC. The power density of a surgical laser beam: its meaning and measurement. Lasers Surg Med 1983; 2:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/12\">",
"      Cavaliere S, Venuta F, Foccoli P, et al. Endoscopic treatment of malignant airway obstructions in 2,008 patients. Chest 1996; 110:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/13\">",
"      Hermens JM, Bennett MJ, Hirshman CA. Anesthesia for laser surgery. Anesth Analg 1983; 62:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/14\">",
"      Perrin G, Colt HG, Martin C, et al. Safety of interventional rigid bronchoscopy using intravenous anesthesia and spontaneous assisted ventilation. A prospective study. Chest 1992; 102:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/15\">",
"      George PJ, Garrett CP, Nixon C, et al. Laser treatment for tracheobronchial tumours: local or general anaesthesia? Thorax 1987; 42:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/16\">",
"      Dumon, JF. Technique of safe laser surgery. Lasers Med Science 1990; 5:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/17\">",
"      Scherer TA. Nd-YAG laser ignition of silicone endobronchial stents. Chest 2000; 117:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/18\">",
"      Ossoff RH, Duncavage JA, Eisenman TS, Karlan MS. Comparison of tracheal damage from laser-ignited endotracheal tube fires. Ann Otol Rhinol Laryngol 1983; 92:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/19\">",
"      Personne C, Colchen A, Bonnette P, et al. Laser in bronchology: methods of application. Lung 1990; 168 Suppl:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/20\">",
"      Tellides G, Ugurlu BS, Kim RW, Hammond GL. Pathogenesis of systemic air embolism during bronchoscopic Nd:YAG laser operations. Ann Thorac Surg 1998; 65:930.",
"     </a>",
"    </li>",
"    <li>",
"     Prakash, US. Bronchoscopy. In: Murray and Nadel's Textbook of Respiratory Medicine, 4th Ed, Mason RJ, Broaddus VC, Murray JF (Eds), Elsevier Saunders, Philadelphia 2005. p.1617-1650.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/22\">",
"      Moghissi K, Dixon K, Hudson E, et al. Endoscopic laser therapy in malignant tracheobronchial obstruction using sequential Nd YAG laser and photodynamic therapy. Thorax 1997; 52:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/23\">",
"      Ramser ER, Beamis JF Jr. Laser bronchoscopy. Clin Chest Med 1995; 16:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/24\">",
"      Quin JA, Letsou GV, Tanoue LT, et al. Use of neodymium yttrium aluminum garnet laser in long-term palliation of airway obstruction. Conn Med 1995; 59:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/25\">",
"      Paleri V, Stafford FW, Sammut MS. Laser debulking in malignant upper airway obstruction. Head Neck 2005; 27:296.",
"     </a>",
"    </li>",
"    <li>",
"     Cavaliere F and Dumon JF. Laser bronchoscopy. In: Interventional bronchoscopy, Bollinger CT, Mathur PN (Eds), Karger AG, Basel, Switzerland 2000. p.108.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38645/abstract/27\">",
"      Colt HG, Harrell JH. Therapeutic rigid bronchoscopy allows level of care changes in patients with acute respiratory failure from central airways obstruction. Chest 1997; 112:202.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4392 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-3D38DFFA37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38645=[""].join("\n");
var outline_f37_47_38645=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9787408\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9788373\">",
"      Principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9788450\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5264479\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9787408\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4392\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4392|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?5/29/5598\" title=\"movie 1\">",
"      Laser photocoagulation of a carcinoid tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?1/43/1727\" title=\"movie 2\">",
"      Laser resection of bronchial carcinoid tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?19/56/20367\" title=\"movie 3\">",
"      Post bronchocscopic laser resection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34823?source=related_link\">",
"      Airway stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24468?source=related_link\">",
"      Argon plasma coagulation in the management of airway disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32151?source=related_link\">",
"      Basic principles of medical lasers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38292?source=related_link\">",
"      Bronchoscopic cryosurgery: Indications, contraindications, and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32038?source=related_link\">",
"      Endobronchial brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11447?source=related_link\">",
"      Endobronchial electrocautery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27126?source=related_link\">",
"      Flexible bronchoscopy balloon dilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37749?source=related_link\">",
"      Photodynamic therapy of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_47_38646="Hypocellular marrow aspirate";
var content_f37_47_38646=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone marrow aspirate in aplastic anemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power (10X) view of a bone marrow aspirate in a patient with aplastic anemia. The supporting stromal meshwork of the bone marrow spicule is outlined by the red arrows. However, hematopoietic cells are sparse, giving the pattern of an empty wicker basket.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38646=[""].join("\n");
var outline_f37_47_38646=null;
var title_f37_47_38647="Extensor tendons traversing wrist";
var content_f37_47_38647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 605px\">",
"   <div class=\"ttl\">",
"    Extensor tendons traversing the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 585px; height: 439px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Upper Limb. In: Clinically Oriented Anatomy, 6th ed, Moore KM, Dalley AF, Agur A (ed), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38647=[""].join("\n");
var outline_f37_47_38647=null;
var title_f37_47_38648="Omeprazole and sodium bicarbonate: Pediatric drug information";
var content_f37_47_38648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Omeprazole and sodium bicarbonate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?10/28/10697?source=see_link\">",
"    see \"Omeprazole and sodium bicarbonate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/27/27061?source=see_link\">",
"    see \"Omeprazole and sodium bicarbonate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16572478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Bone Fracture Risk with Proton Pump Inhibitors: Health Canada Issues Alert",
"     </span>",
"     <span class=\"collapsible-date\">",
"      April 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has informed healthcare professionals that proton pump inhibitors (PPIs) may increase the risk of bone fractures. The risk of fracture was observed to be higher in patients receiving multiple daily doses for &ge;1 year; age, gender, and concomitant health conditions may also be a factor. Patients with risk factors for osteoporosis should be closely monitored and should receive a PPI at the lowest effective dose and for the shortest duration of therapy appropriate for the condition.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26523a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2874244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zegerid OTC&trade; [OTC];",
"     </li>",
"     <li>",
"      Zegerid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F5932829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Proton Pump Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Substituted Benzimidazole",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F5932840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/28/10697?source=see_link\">",
"      see \"Omeprazole and sodium bicarbonate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Dosage listed that of omeprazole component",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children: GERD, ulcers, esophagitis;",
"     <b>",
"      Note:",
"     </b>",
"     Recognizing that this formulation has not received FDA approval for use in children despite an approved dosage for omeprazole in children and considering that omeprazole has been used safely in children as an extemporaneous formulation with sodium bicarbonate, the following dosage is recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     5 kg to &lt;10 kg: 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     10 kg to &le;20 kg: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;20 kg: 20 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alternate dosing: 1 mg/kg/day once or twice daily; range of effective dosages in the literature: 0.2-3.5 mg/kg/day (Hassall, 2000; Zimmermann, 2001). Higher doses may be necessary in children between 1-6 years of age due to increased metabolic clearance (Andersson, 2000). To maintain gastric pH &gt;5 in critically-ill children, administration every 6-8 hours may be necessary (1.5-2 mg/kg/day) (Kaufman, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Active duodenal ulcer: 20 mg/day for 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastric ulcers: 40 mg/day for 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     GERD or severe erosive esophagitis: 20 mg/day for 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Heartburn: OTC labeling: 20 mg once daily for 14 days. Do not take for &gt;14 days or more often than every 4 months, unless instructed by healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance of healing of erosive esophagitis: 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Bioavailability is increased with chronic liver disease. Consider dosage adjustment, especially for maintenance of healing of erosive esophagitis. Specific guidelines are not available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2874302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: Omeprazole 20 mg [immediate release] and sodium bicarbonate 1100 mg; omeprazole 40 mg [immediate release] and sodium bicarbonate 1100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zegerid&reg;: Omeprazole 20 mg [immediate release] and sodium bicarbonate 1100 mg [contains sodium 304 mg (13 mEq) per capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zegerid&reg;: Omeprazole 40 mg [immediate release] and sodium bicarbonate 1100 mg [contains sodium 304 mg (13 mEq) per capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zegerid OTC&trade;: Omeprazole 20 mg [immediate release] and sodium bicarbonate 1100 mg [contains sodium 303 mg (13 mEq) per capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zegerid&reg;: Omeprazole 20 mg and sodium bicarbonate 1680 mg per packet (30s) [contains sodium 460 mg (20 mEq) per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zegerid&reg;: Omeprazole 40 mg and sodium bicarbonate 1680 mg per packet (30s) [contains sodium 460 mg (20 mEq) per packet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2874245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15664179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Zegerid&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM328349.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM328349.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5932841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Both strengths of capsule and Zegerid&reg; powder for oral suspension have identical sodium bicarbonate content, respectively. Do not substitute two 20 mg capsules/packets for one 40 mg dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule: Should be swallowed whole with water (do not use other liquids); do not chew or crush. Capsules should",
"     <b>",
"      not",
"     </b>",
"     be opened, sprinkled on food, or administered via NG.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for oral suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Administer 1 hour before a meal. Mix with 30 mL of water; stir well and drink immediately. Rinse cup with water and drink.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nasogastric/orogastric tube: Mix well with 20 mL of water and administer immediately; flush tube with an additional 20 mL of water. Suspend enteral feeding for 3 hours before and 1 hour after administering.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F5932837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5932830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term (4-8 weeks) treatment of active duodenal ulcer disease or active benign gastric ulcer; treatment of symptomatic gastroesophageal reflux disease (GERD) (FDA approved in adults); treatment and maintenance healing of erosive esophagitis; reduction of risk of upper gastrointestinal bleeding in critically ill patients (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     OTC labeling: Relief of frequent (&ge;2 days/week), uncomplicated heartburn (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7913703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zegerid&reg; may be confused with Zestril&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F2874261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation, bradycardia, edema, hyper-/hypotension, supraventricular tachycardia, tachycardia, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, hyperpyrexia, pyrexia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatological: Decubitus ulcer, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid overload, hyper-/hypoglycemia, hyper-/hypokalemia, hyper-/hyponatremia, hypocalcemia, hypomagnesemia, hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, hypomotility",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematological: Anemia, anemia increased, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: LFTs increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: ARDS, cough, nosocomial pneumonia, pneumothorax, respiratory failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Candidal infection, oral candidiasis, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening (adverse event occurrence may vary based on formulation): Agranulocytosis, allergic reactions, alopecia, anaphylaxis, angina, angioedema, anorexia, atrophic gastritis, benign gastric polyps, bronchospasm,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD), creatinine increased, depression, erythema multiforme, esophageal candidiasis, fracture, glycosuria, gynecomastia, hallucinations, hematuria, hemifacial dysesthesia, hemolytic anemia, hepatic encephalopathy, hepatic failure, hepatic necrosis interstitial nephritis, hypersensitivity, leukocytosis, leukopenia, liver disease (hepatocellular, cholestatic, mixed), metabolic alkalosis, microscopic pyuria, microscopic colitis, mucosal atrophy (tongue), neutropenia, optic neuritis, optic neuropathy, osteoporosis-related fracture, pancreatitis, pancytopenia, photosensitivity, pneumonia (CAP), proteinuria, psychiatric disturbance, purpura, seizure, Stevens-Johnson syndrome, taste perversion, tinnitus, toxic epidermal necrolysis, vertigo, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5932832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to omeprazole, substituted benzimidazole proton pump inhibitors (eg, esomeprazole, lansoprazole), or any component.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F7294298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with Bartter's syndrome, hypokalemia, and respiratory alkalosis due to high content of sodium bicarbonate; avoid use in patients on sodium-restrictive diets; chronic use may lead to systemic alkalosis, edema, and weight gain. Bioavailability may be increased in patients with hepatic dysfunction or patients of Asian descent; consider dosage reductions, especially for maintenance healing of erosive esophagitis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5932833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In long-term (2-year) studies in rats, omeprazole produced a dose-related increase in gastric carcinoid tumors. While available endoscopic evaluations and histologic examinations of biopsy specimens from human stomachs have not detected a risk from short-term exposure to omeprazole, further human data on the effect of sustained hypochlorhydria and hypergastrinemia are needed to rule out the possibility of an increased risk for the development of tumors in humans receiving long-term therapy. An increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy; patients on high-dose or long-term therapy should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk. Hypomagnesemia has been reported rarely, usually with prolonged PPI use of &gt;3 months (most cases &gt;1 year of therapy), and may be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter. Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of omeprazole may be necessary; magnesium concentrations typically return to normal within 1 week of stopping. Atrophic gastritis has been reported occasionally in gastric corpus biopsies from patients treated long-term with omeprazole. Symptomatic response to therapy does not preclude the presence of GI malignancy. Use of gastric acid inhibitors, including proton pump inhibitors and H2 blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia (Canani, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2874267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2874266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AcetaZOLAMIDE: May enhance the adverse/toxic effect of Sodium Bicarbonate. Specifically, the risk of renal calculus formation may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Alkalinizing Agents may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Proton Pump Inhibitors may increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Proton Pump Inhibitors may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Omeprazole may enhance the adverse/toxic effect of Cilostazol. Omeprazole may increase the serum concentration of Cilostazol. Omeprazole may increase the serum concentration of  OPC-13015, an active metabolite of Cilostazol.  Management: Monitor for increased effects of cilostazol when coadministered with omeprazole. Consider a 50% dose reduction of cilostazol (eg, 100 mg twice daily to 50 mg twice daily) with concomitant use of these agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Omeprazole may decrease the serum concentration of CloZAPine. Omeprazole may increase the serum concentration of CloZAPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Omeprazole may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Escitalopram: Omeprazole may increase the serum concentration of Escitalopram.  Management: Monitor for increased escitalopram toxicity with concomitant use of omeprazole. Escitalopram dosing recommendations may differ between international labelings in regards to concomitant use of omeprazole. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Sodium Bicarbonate may diminish the arrhythmogenic effect of Flecainide. Sodium Bicarbonate may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Proton Pump Inhibitors may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Sodium Bicarbonate may increase the excretion of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Sodium Bicarbonate may decrease the excretion of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Proton Pump Inhibitors may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Proton Pump Inhibitors may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Alkalinizing Agents may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Omeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Omeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Omeprazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.  Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5932836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration of omeprazole powder for suspension 1 hour after a meal reduced the AUC by 24% and peak plasma level by 63%.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2874251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2874252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies with omeprazole. Based on data collected by the Teratogen Information System (TERIS), it was concluded that therapeutic doses used during pregnancy would be unlikely to pose a substantial teratogenic risk (quantity/quality of data: fair). Because the possibility of harm still exists, the manufacturer recommends use during pregnancy only if the potential benefit to the mother outweighs the possible risk to the fetus. Chronic use of sodium bicarbonate-containing products may lead to systemic alkalosis, edema, and weight gain; metabolic alkalosis and fluid overload may occur in mother and fetus.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5932838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppresses gastric acid secretion by inhibiting the parietal cell membrane enzyme (H",
"     <sup>",
"      +",
"     </sup>",
"     /K",
"     <sup>",
"      +",
"     </sup>",
"     )-ATPase or proton pump; demonstrates antimicrobial activity against",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F7294406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 72 hours; 50% of maximum effect at 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum secretory inhibition: 4 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5932839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP2C19 primarily and to a lesser extent via 3A4 to hydroxy, desmethyl, and sulfone metabolites (all inactive); saturable first pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 30% to 40%; improves slightly with repeated administration; increased in Asian patients and patients with hepatic dysfunction; excreted into breast milk (peak concentration in breast milk &lt;7% of corresponding peak plasma concentration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: ~1 hour (range: 0.4-3.2 hours); chronic hepatic disease: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance: Adults: 500-600 mL/minute; chronic hepatic disease: 70 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F5932842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/27/27061?source=see_link\">",
"      see \"Omeprazole and sodium bicarbonate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F7294407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Each capsule of omeprazole-sodium bicarbonate contains 1100 mg (13 mEq) of sodium bicarbonate; total Na content is 304 mg and 303 mg for the prescription and OTC product, respectively. Each packet of omeprazole-sodium bicarbonate powder for oral suspension contains 1680 mg (20 mEq) of sodium bicarbonate; total Na content is 460 mg.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11430489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 2 mg/mL oral suspension may be made with omeprazole-sodium bicarbonate powder and water. Pour the contents of six 20 mg omeprazole-sodium bicarbonate packets into a glass mortar. Add 30 mL water to the powder and mix to a uniform paste; mix while adding water in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     60 mL; transfer to a 60 mL bottle, rinse mortar with water, and add sufficient quantity of water to make 60 mL. Label \"shake well\" and \"refrigerate\". Stable for 45 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Johnson CE, Cober MP, and Ludwig JL, \"Stability of Partial Doses of Omeprazole-Sodium Bicarbonate Oral Suspension,\"",
"     <i>",
"      Ann Pharmacother",
"     </i>",
"     , 2007, 41(12):1954-61.",
"     <span class=\"pubmed-id\">",
"      17956960",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andersson T, Hassall E, Lundborg P, et al, &ldquo;Pharmacokinetics of Orally Administered Omeprazole in Children. International Pediatric Omeprazole Pharmacokinetic Group,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2000, 95(11):3101-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/47/38648/abstract-text/11095324 /pubmed\" id=\"11095324 \" target=\"_blank\">",
"        11095324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canani RB, Cirillo P, Roggero P, et al, \"Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(5):e817-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/47/38648/abstract-text/16651285/pubmed\" id=\"16651285\" target=\"_blank\">",
"        16651285",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gibbons TE and Gold BD, &ldquo;The Use of Proton Pump Inhibitors in Children: A Comprehensive Review,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2003, 5(1):25-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/47/38648/abstract-text/12513104/pubmed\" id=\"12513104\" target=\"_blank\">",
"        12513104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gottrand F, Kalach N, Spyckerelle C, et al, &ldquo;Omeprazole Combined With Amoxicillin and Clarithromycin in the Eradication of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      in Children With Gastritis: A Prospective Randomized Double-Blind Trial,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 139(5):664-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/47/38648/abstract-text/11713443/pubmed\" id=\"11713443\" target=\"_blank\">",
"        11713443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gunasekaran TS and Hassall EG, &ldquo;Efficacy and Safety of Omeprazole for Severe Gastroesophageal Reflux in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1993, 123(1):148-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/47/38648/abstract-text/ 8320610 /pubmed\" id=\" 8320610 \" target=\"_blank\">",
"        8320610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hassall E, Israel D, Shepherd R, &ldquo;Omeprazole for Treatment of Chronic Erosive Esophagitis in Children: A Multicenter Study of Efficacy, Safety, Tolerability and Dose Requirements. International Pediatric Omeprazole Study Group,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2000, 137(6):800-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/47/38648/abstract-text/11113836/pubmed\" id=\"11113836\" target=\"_blank\">",
"        11113836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson CE, Cober MP, and Ludwig JL, \"Stability of Partial Doses of Omeprazole-Sodium Bicarbonate Oral Suspension,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2007, 41(12):1954-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/47/38648/abstract-text/17956960/pubmed\" id=\"17956960\" target=\"_blank\">",
"        17956960",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kane DL, &ldquo;Administration of Omeprazole (Prilosec&trade;) in the Atypical Patient,&rdquo;",
"      <i>",
"       Int J Pharm Compounding",
"      </i>",
"      , 1997, 1(1):13.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kato S, Ebina K, Fujii K, et al, &ldquo;Effect of Omeprazole in the Treatment of Refractory Acid-Related Diseases in Childhood: Endoscopic Healing and Twenty-Four Hour Intragastric Acidity,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1996, 128(3):415-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/47/38648/abstract-text/8774516 /pubmed\" id=\"8774516 \" target=\"_blank\">",
"        8774516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaufman SS, Lyden ER, Brown CR, et al, &ldquo;Omeprazole Therapy in Pediatric Patients After Liver and Intestinal Transplantation,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2002, 34(2):194-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/47/38648/abstract-text/11840039/pubmed\" id=\"11840039\" target=\"_blank\">",
"        11840039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Song JC, Quercia RA, Fan C, et al, &ldquo;Pharmacokinetic Comparison of Omeprazole Capsules and a Simplified Omeprazole Suspension,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2001, 58(8):689-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/47/38648/abstract-text/11329761/pubmed\" id=\"11329761\" target=\"_blank\">",
"        11329761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zimmermann AE, Walters JK, Katona BG, et al, &ldquo;A Review of Omeprazole Use in the Treatment of Acid-Related Disorders in Children,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2001, 23(5):660-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/47/38648/abstract-text/11394727/pubmed\" id=\"11394727\" target=\"_blank\">",
"        11394727",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13068 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38648=[""].join("\n");
var outline_f37_47_38648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16572478\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874244\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5932829\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5932840\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874302\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874245\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15664179\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5932841\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5932837\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5932830\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7913703\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874261\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5932832\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7294298\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5932833\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874267\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874266\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5932836\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874251\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2874252\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5932838\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7294406\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5932839\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5932842\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7294407\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11430489\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13068\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13068|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/28/10697?source=related_link\">",
"      Omeprazole and sodium bicarbonate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/27/27061?source=related_link\">",
"      Omeprazole and sodium bicarbonate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_47_38649="Dietary carbohydrates";
var content_f37_47_38649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dietary carbohydrates",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/47/38649/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38649/contributors\">",
"     Simin Liu, MD, ScD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38649/contributors\">",
"     Walter C Willett, MD, DrPh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/47/38649/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38649/contributors\">",
"     F Xavier Pi-Sunyer, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38649/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/47/38649/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38649/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/47/38649/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widespread promotion of low-fat diets in the 1980s and 1990s led to a reduction in the percentage of calories from fat in the US diet and a concurrent increase in carbohydrate intake. Despite these dietary changes, the prevalence of obesity and type 2 DM continued to rise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/1\">",
"     1",
"    </a>",
"    ]. Perhaps partly due to unsatisfactory outcomes with low-fat diets, a large segment of the population that wants to lose weight is increasingly following many popular diets that emphasize low- or no-carbohydrates for weight loss.",
"   </p>",
"   <p>",
"    In the scientific community, serious concern has also been raised over dietary recommendations for high-carbohydrate, low-fat diets. High-carbohydrate diets reduce high-density lipoprotein cholesterol (HDL) and raise blood concentrations of glucose, insulin, and triglyceride and blood pressure, contributing to a now well-recognized metabolic profile called insulin resistance syndrome that is conducive for the development of CHD and type 2 DM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the differences in chemical structure, physical form, fiber content, and the degree of processing (refining and gelatinization), different forms of carbohydrates are likely to have heterogeneous biological functions and health effects. These effects are discussed here. Overall recommendations for a prudent diet are found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31641?source=see_link\">",
"     \"Healthy diet in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF CARBOHYDRATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbohydrates are traditionally classified as simple (sugars, ie, mono- and disaccharides) or complex (starches, ie, polysaccharides) on the basis of the number of sugar molecules in their chemical structures. It had been assumed that complex carbohydrates cause smaller rises in blood glucose than simple carbohydrates. Dietary guidelines for individuals with diabetes mellitus (DM) that recommend the use of complex rather than simple carbohydrates to control blood glucose levels reflect this assumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A growing body of data, however, contradicts this notion. In the mid-1970s, the first series of studies were published in the English literature showing that various starchy foods differ in their ability to induce plasma glucose and insulin responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. These findings initiated a new era of research on the in vivo physiologic effects of carbohydrates. Collectively, these data demonstrate that digestion of carbohydrates, particularly starch, is not a rate-limiting event and is often quite rapid because of the presence of sufficient amylolytic capacity in the intestine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/8\">",
"     8",
"    </a>",
"    ]. As an example, postprandial glycemic responses to potato and white bread are similar to the response to pure glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], indicating that complex carbohydrates may not differ from simple sugars in their effect on plasma glucose level.",
"   </p>",
"   <p>",
"    Thus, carbohydrates can be classified by their glycemic index, indicating their effect on blood glucose. In addition, carbohydrates can be characterized by their fiber content, which refers to undigested carbohydrate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/11\">",
"     11",
"    </a>",
"    ]. The fiber content also reflects the content of minerals, vitamins, and other biologically active constituents. Finally, dissolving carbohydrate in water, typically as sugar-sweetened beverages, has important effects on satiety. Thus, whether carbohydrates are consumed in solid or liquid form needs to be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GLYCEMIC INDEX",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;An in vivo measure of the relative impact of carbohydrate-containing foods on blood glucose is the glycemic index (GI). A particular food's GI is determined by evaluating the incremental rises of blood glucose after ingestion of a food that contains 50 g of carbohydrate compared with the same amount of carbohydrate from a reference food, usually white bread or glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following values are generally applied for defining the GI of a particular food (using glucose as a reference):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low GI &ndash; 55 or less",
"     </li>",
"     <li>",
"      Medium GI &ndash; 56 to 69",
"     </li>",
"     <li>",
"      High GI &ndash; 70 or more",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Determination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GI of a food depends upon the rapidity of digestion and absorption of its dietary carbohydrates, which is largely determined by both its physical and chemical properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Typically, foods with a low degree of starch gelatinization, such as pasta, and those containing a high level of viscous soluble fiber, such as whole-grain barley, oats, and rye, have slower rates of digestion and lower GI values.",
"   </p>",
"   <p>",
"    Another important influence on GI values is the ratio of amylose (a linear-chain molecule of 300 to 600 glucose residues linked by a-1,4-glucosidic bonds) to amylopectin (a larger, highly branched polymer of 6000 glucose residues linked by both a-1,4- and a-1,6-glucosidic bonds). Foods with a higher",
"    <span class=\"nowrap\">",
"     amylose/amylopectin",
"    </span>",
"    ratio, such as legumes and parboiled rice, tend to have lower GI values, likely due to the compact structure of amylose, which physically slows enzymatic reactions. In contrast, the branched structure of amylopectin is open to enzymatic attack and is thus easily digested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Utility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of the GI has shown that many complex carbohydrates induce glycemic and insulinemic responses nearly as high as those induced by pure glucose, thereby further casting doubt on the usefulness of the simple versus complex classification system. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Classification of carbohydrates'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The pros and cons of the GI concept have been debated since its introduction in the 1980s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The debate originated from evaluating what kind of dietary carbohydrate is best for controlling postprandial glycemia in the medical nutrition therapy of diabetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/20\">",
"     20",
"    </a>",
"    ]. Concerns raised about the clinical usefulness of the GI revolve around two major issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/2,18,21\">",
"     2,18,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The usefulness of the GI for mixed meals",
"     </li>",
"     <li>",
"      The lack of long-term studies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Mixed meals",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early 1980s, three studies showed that when individual carbohydrate foods were taken as part of a mixed meal, differences in glycemic responses between foods no longer existed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The authors postulated that these findings were due to the effects of fat and protein on glycemic responses. Although the methodology of these studies has been criticized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/18\">",
"     18",
"    </a>",
"    ], the results were used by the 1986 NIH consensus conference on diet and exercise in type 2 diabetes mellitus (DM) to reject the use of the GI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since then, many studies aimed at addressing these concerns have been conducted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/24-26\">",
"     24-26",
"    </a>",
"    ], and there are now abundant data to support the GI concept [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In particular, several studies have shown that although fat and protein affect the absolute glycemic response, they do not affect the relative differences between foods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/14\">",
"     14",
"    </a>",
"    ]. In other words, given the same amount of protein and fat in a meal, high glycemic foods still lead to a higher glycemic response than do low glycemic foods. Studies using standardized methodology have indicated that the correlation between the GI of mixed meals and the average GI values of individual component foods ranges from 0.84 to 0.99 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/14,28\">",
"     14,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Long-term data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controversy regarding the clinical usefulness of the GI continues, mainly due to the lack of long-term data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/20,29\">",
"     20,29",
"    </a>",
"    ]. Most metabolic studies of GI are of very short duration, on the order of several meals or several days worth of meals. This has become a contentious point, with editorials and commentaries calling for long-term studies to assess the clinical usefulness of the GI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GLYCEMIC LOAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;A principal argument against the glycemic index (GI) concept is that it cannot capture the entire glucose-raising potential of dietary carbohydrates because the blood glucose response is influenced by the quantity of carbohydrate consumed as well as the quality (the latter reflected in the GI). To address this concern, the concept of glycemic load (GL) was introduced. Defined as the product of the GI value of a food and its carbohydrate content, GL incorporates both the quality and quantity of carbohydrate consumed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With white bread used as the reference standard, dietary GL quantifies the glucose raising potential of dietary carbohydrates, with each unit of dietary GL representing the equivalent glycemic effect of 1 g of carbohydrate from white bread. In general, carbohydrate-rich foods with low fiber content have high GI and GL values; examples include potatoes, refined cereal products, and many sugar-sweetened beverages. In contrast, whole grains, fruits, and vegetables with high fiber content provide low to very low GLs per serving.",
"   </p>",
"   <p>",
"    Many low GI foods are not necessarily high in fiber (eg, pasta, Basmati rice, and dairy products), while some high-fiber whole-meal bread and cereal products (eg, Raisin Bran and Wheaties) are high in GI. This highlights the importance of determining GI values of food products through direct testing. Such testing has distinguished two types of available glucose from foods (most foods contain a mixture of starch and sugars), termed rapidly available glucose (RAG) and slowly available glucose (SAG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/32\">",
"     32",
"    </a>",
"    ]. In two studies that examined a total of 64 food products, the RAG values were significantly correlated with both their direct glycemic response and published GI values, supporting the physiologic relevance of this in vitro categorization of RAG and SAG in foods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following values are generally applied for defining the GL of a particular food (per serving, using glucose as a reference):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low GL &ndash; 10 or less",
"     </li>",
"     <li>",
"      Medium GL &ndash; 11 to 19",
"     </li>",
"     <li>",
"      High GL &ndash; 20 or more",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following values are generally applied for defining the GL per day:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low GL &ndash; Less than 80",
"     </li>",
"     <li>",
"      High GL &ndash; More than 120",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIETARY CARBOHYDRATES AND WEIGHT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Grains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relatively few studies have directly examined the effects of specific types of carbohydrate-rich foods on weight changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/34\">",
"     34",
"    </a>",
"    ]. Due to their high fiber and water content, whole grain foods contain fewer calories gram for gram than the isovolemic amount of the corresponding refined grain foods. Whole grains may protect against weight gain through several mechanisms that involve effects on satiety, post-load glucose and insulin responses, and antioxidant properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several large prospective studies have found that intake of whole grains, as opposed to refined grains, is inversely associated with body weight and fat distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Coronary Artery Risk Development in Young Adults Study (CARDIA), intake of whole grains was inversely associated with body mass index (BMI) at all levels of fat intake and predicted insulin levels, 10-year weight gain, and other cardiovascular disease risk factors including blood pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/36\">",
"       36",
"      </a>",
"      ]. Participants in the highest category of whole grain intake (&gt;21",
"      <span class=\"nowrap\">",
"       g/2000",
"      </span>",
"      kcal) gained approximately 3.6 kg (8 lb) less in weight than those in the lowest category of intake (&lt;12",
"      <span class=\"nowrap\">",
"       g/2000",
"      </span>",
"      kcal).",
"     </li>",
"     <li>",
"      In the Nurses' Health Study (NHS) of middle-aged women, participants with the greatest increase in intake of whole grain gained an average of 1.52 kg less than those with the smallest increase in intake, independent of body weight at baseline, age, and changes in covariate status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/35\">",
"       35",
"      </a>",
"      ]. Women in the highest quintile of whole grain intake had a 49 percent lower risk of major weight gain than women in the highest quintile of refined grain intake (OR = 0.51, 95% CI 0.39-0.67).",
"     </li>",
"     <li>",
"      A prospective investigation of dietary patterns among 120,877 men and women apparently free of chronic diseases reported that increasing whole grain intake by one",
"      <span class=\"nowrap\">",
"       serving/day",
"      </span>",
"      was positively associated with a modest 0.37 pound reduction in body weight over a four-year period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effect of glycemic index/glycemic load",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manipulation of dietary glycemic index (GI) or glycemic load (GL) has emerged as an important approach to weight control. Short-term feeding trials have shown that carbohydrate absorption after a meal is inversely proportional to satiety and directly related to increased caloric intake. Since the duration of post-meal satiety is generally related to postprandial glycemia, low GI foods have been hypothesized to reduce the hunger signal and delay the onset of next meals.",
"   </p>",
"   <p>",
"    This concept was examined in a randomized trial that compared the hormonal and metabolic changes associated with isocaloric meals differing only in GI and GL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/39\">",
"     39",
"    </a>",
"    ]. Blood glucose and fatty acid concentrations were significantly lower, while counter-regulatory hormones were elevated in high GI diets three to five hours after ingestion.",
"   </p>",
"   <p>",
"    Similarly, a randomized trial compared the effects of a low-GL diet (total daily GL 82) and a low-fat diet (total daily GL 205) on resting energy expenditure (REE) and CHD risk factors in 39 young adults during a diet designed to provide 60 percent of energy requirements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/40\">",
"     40",
"    </a>",
"    ]. After subjects had lost 10 percent of their baseline body weight, REE had decreased less in those on a low-GL diet (-96 versus -176",
"    <span class=\"nowrap\">",
"     kcal/day),",
"    </span>",
"    and hunger was also less on the low-GL diet. The diets had similar effects on HDL and LDL levels, but those on the low-GL diet had greater decreases in triglycerides (-3.5 versus +16.2 percent), C-reactive protein (-47.7 versus -5.1 percent), and on a measure of insulin resistance (-33.9 versus -15.8 percent). There was also a trend toward a larger decrease in systolic and diastolic blood pressure on the low-GL diet. These results suggest that a low-GL diet can reduce some of the physiologic adaptations to a low calorie diet (decreased REE, hunger) that interfere with sustained weight loss, while achieving an improved CHD-risk profile.",
"   </p>",
"   <p>",
"    Other trials also suggest weight loss and CHD-risk benefits with low-GI diets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. In a meta-analysis of six trials (202 participants) comparing a low GI diet with a higher GI diet or a conventional calorie-restricted reduced fat diet, short-term weight loss (weighted mean difference 1.1 kg) and reduction in LDL cholesterol (-0.24",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    were significantly greater in the low GI diet group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/44\">",
"     44",
"    </a>",
"    ]. There were no trials lasting more than six months, and therefore the long-term benefits of a low GI diet are unknown.",
"   </p>",
"   <p>",
"    Baseline insulin secretion may predict weight loss with low-GL diets. This was illustrated in a randomized trial of obese, young adults assigned to a low-GL or low-fat diet after baseline assessment of insulin secretion (serum insulin concentration measured 30 minutes after a 75 g oral glucose load) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/45\">",
"     45",
"    </a>",
"    ]. At 18-months of follow-up, patients with higher insulin concentrations lost more weight and body fat with the low-GL diet than with the low-fat diet. In contrast, in patients with lower insulin secretion, both diets produced similar results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Very low carbohydrate diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"very low carbohydrate diet,\" among different practitioners, refers to diets that contain anywhere from 0 to &lt;60 grams of carbohydrates, or approximately 0 to 10 percent of dietary energy derived from carbohydrate.",
"   </p>",
"   <p>",
"    The impact of very low-carbohydrate diets on weight loss has been examined in several randomized trials. Studies have varied in type of population, design, and intensity of intervention. These trials are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=see_link&amp;anchor=H10#H10\">",
"     \"Dietary therapy for obesity\", section on 'Low-carbohydrate diets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In brief, the findings from the trials show that very low-carbohydrate diets are safe with regard to serum lipids and are more effective for short-term weight loss than low-fat diets. However, the impact of macronutrient composition on long-term weight loss remains a contentious area. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=see_link&amp;anchor=H14#H14\">",
"     \"Dietary therapy for obesity\", section on 'Comparison trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIETARY CARBOHYDRATES AND DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several prospective studies have associated diets high in GI and GL with risk of developing some chronic diseases. In two meta-analyses of 37 observational studies of GI and GL and risk of chronic disease, significant positive associations were found for type 2 diabetes mellitus, coronary heart disease, gallbladder disease, and breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The potential mechanisms by which carbohydrates contribute to the risk of developing these chronic diseases are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diabetes and metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to insulin-mediated glucose transport is a fundamental early defect in the pathogenesis of type 2 diabetes mellitus (DM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=see_link\">",
"     \"Pathogenesis of type 2 diabetes mellitus\"",
"    </a>",
"    .) Among individuals with impaired insulin action, glucose homeostasis can be maintained through increased insulin production. In some individuals, hyperglycemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    compensatory hyperinsulinemia (increased insulin production) make the pancreatic beta cells eventually lose their responsiveness to glucose, ultimately leading to the development of clinical diabetes.",
"   </p>",
"   <p>",
"    While mechanisms for the so-called insulin resistance-pancreatic exhaustion phenomenon are not fully understood, it has been clearly established, at least in animal models, that glucose toxicity contributes to insulin resistance and defects in insulin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/49\">",
"     49",
"    </a>",
"    ]. Regardless of the ultimate dietary source of glucose, however, animal models show that postprandial hyperglycemia contributes to insulin resistance and defects in insulin secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/50\">",
"     50",
"    </a>",
"    ]. Among individuals with diabetes, a chronic increment in the plasma glucose concentration causes defects in insulin secretion and may lead to insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/51\">",
"     51",
"    </a>",
"    ]. Thus, dietary factors that increase plasma glucose and insulin responses may aggravate the effects of insulin resistance that, in turn, may increase the risk of type 2 DM. Conversely, dietary factors that minimize both glycemic and insulinemic responses may protect against the development of type 2 DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal studies have demonstrated adverse effects of diets very high in fructose or sucrose on insulin sensitivity and hypertriglyceridemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/52\">",
"     52",
"    </a>",
"    ]. Similarly, a study in which partially pancreatectomized rats were given diets with identical nutrients except for the type of starch (either high- or low-glycemic index, GI) found that rats given the high-GI food had almost twice the body fat of the rats given low-GI food after nine weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, the high-GI group had greater increases over time in blood glucose and plasma insulin after oral glucose and higher plasma triglyceride concentrations.",
"   </p>",
"   <p>",
"    Because of limited data in humans, however, controversies remain regarding the role of sugars in the development of insulin resistance and type 2 DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/1,54\">",
"     1,54",
"    </a>",
"    ]. Similarly, few studies have examined the relation between starch types and insulin resistance in humans. Partly because of the difficulties involved in assessing whole-body insulin sensitivity, studies of dietary GI in humans have focused primarily on markers of insulin resistance, including levels of postprandial glucose, insulin, C-peptide, and fasting TG. Most studies show reduced glycemic and insulin responses to a low-GI meal as compared with a high-GI meal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9610?source=see_link&amp;anchor=H11#H11\">",
"     \"Risk factors for type 2 diabetes mellitus\", section on 'Dietary patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, reductions in plasma levels of glucose, insulin, or C-peptide, and improvement in insulin sensitivity, have been shown among patients with DM, coronary heart disease (CHD), or postmenopausal women who switched from a high-GI to a low-GI diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/24,25,55-57\">",
"     24,25,55-57",
"    </a>",
"    ]. In meta-analyses of trials comparing low and high glycemic index diets in individuals with either type 1 or type 2 diabetes, low GI diets significantly reduced A1C by 0.4 to 0.5 percentage points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. This compares favorably to the carbohydrate exchange concept in terms of glycemic control among patients with diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/18/14634?source=see_link&amp;anchor=H20#H20\">",
"     \"Nutritional considerations in type 2 diabetes mellitus\", section on 'Nutritional content'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the reduction in A1C is modest (0.4 to 0.5 percentage points), it is comparable to the approximately 0.5 percent unit changes in A1C typically achieved with the drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/60,61\">",
"     60,61",
"    </a>",
"    ], which delays carbohydrate digestion through inhibiting glucosidase in the small intestine. Thus, dietary approaches to the prevention and control of diabetes should thus be given at least as much attention as drug therapies, since a low-GI diet may improve glycemic control to the same extent as some pharmacological agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3078?source=see_link\">",
"     \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the results of metabolic studies suggest that long-term consumption of low-GI carbohydrates should reduce the risk of type 2 DM, direct evaluation of this hypothesis in human populations in a randomized experimental setting would be extremely difficult if not impossible. First, the feasibility of such a trial is unclear because it would require a large number of subjects and many years of follow-up. Second, given the clear clinical efficacy of glucosidase inhibitors, that work specifically by reducing postprandial glycemia, for prevention of type 2 DM and coronary heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/62\">",
"     62",
"    </a>",
"    ], conducting a randomized trial to evaluate the effects of a high versus low glycemic diet on DM risk may not be ethical. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary intervention studies have shown increased levels of fasting TG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/63\">",
"     63",
"    </a>",
"    ] and lower levels of HDL when participants are put on high-carbohydrate diets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/64\">",
"     64",
"    </a>",
"    ]. The exact molecular mechanism remains uncertain but may include enhanced hepatic synthesis of LDL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/65\">",
"     65",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduced lipoprotein lipase activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/66\">",
"     66",
"    </a>",
"    ]. High-GI diets may also increase fat disposition by reducing the oxidation of stored fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prospective cohort studies show that dietary GI and GL are associated with risk factors for CHD and with risk of CHD itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/31,69-71\">",
"     31,69-71",
"    </a>",
"    ]. In a meta-analysis of 10 prospective studies, individuals in the highest compared with lowest GI quantile (84.4 versus 72.3 GI units) had an increase in CHD risk (RR 1.27, 95% CI 0.99-1.24) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/72\">",
"     72",
"    </a>",
"    ]. The effect of high GI diet on risk of CHD was significantly greater in women (RR 1.26, 95% CI 1.12-1.41) but not in men (RR 0.96, 95% CI 0.84-1.11). Similar findings were noted for women and men in the highest compared with lowest GL quantile (224.8 versus 135.4 GL units).",
"   </p>",
"   <p>",
"    In one of the larger cohorts included in the meta-analysis, the Nurses&rsquo; Health Study with 75,521 healthy middle-aged women, the risk was present after 20 years of follow-up (RR of CHD comparing the highest and lowest deciles of glycemic load 1.90, 95% CI 1.15-3.15) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/69\">",
"     69",
"    </a>",
"    ]. In this study, a significant interaction with body mass index (BMI) was seen: there was little association between dietary GL and CHD risk among the leanest women (BMI less than 23), but a strong positive association was observed among heavier women. A separate analysis from the Nurses&rsquo; Health Study did not find an association between stroke and either GI or GL, but did find a positive association between total carbohydrate intake and risk of hemorrhagic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/73\">",
"     73",
"    </a>",
"    ]. BMI also appeared to modify the association between dietary GL and stroke: no association was seen among women with a BMI less than 25, but a significant positive association was seen among heavier women. Consumption of cereal fiber was associated with a lower risk of stroke.",
"   </p>",
"   <p>",
"    Although the observational data support an association between GI and GL and CHD, there are no direct clinical trial data to show whether manipulation of dietary GI or GL will prevent or delay the development of CHD in nondiabetic or diabetic populations. However, low",
"    <span class=\"nowrap\">",
"     GI/GL",
"    </span>",
"    diets appear to have beneficial effects on CHD risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized trials conducted among overweight or obese men provided support of the usefulness of GI in influencing metabolic parameters. In a crossover trial of 11 obese men that lasted for three weeks, plasma lipid profiles and CHD risk profiles with three different dietary regimens were compared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      American Heart Association [AHA] step-1 diet (a low-fat diet)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Low-GI/low-fat/high-protein",
"      </span>",
"      diet",
"     </li>",
"     <li>",
"      The AHA step-1 diet energy-matched to regimen 2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Men on the",
"    <span class=\"nowrap\">",
"     low-GI/low-fat/high-protein",
"    </span>",
"    diet, as opposed to those on the AHA step-1 diet, showed significant reductions in plasma insulin and lipids levels. Of particular interest, compared with the men on the AHA step-1 diet, men on the",
"    <span class=\"nowrap\">",
"     low-GI/low-fat/high-protein",
"    </span>",
"    diet had a significant 25 percent reduction in spontaneous energy intake that did not increase hunger or decrease satiety.",
"   </p>",
"   <p>",
"    In another randomized trial of 11 overweight men that lasted for five weeks, a similar improvement in lipid profile was observed when participants were in the low-GI diet period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/75\">",
"     75",
"    </a>",
"    ]. Although no significant changes in insulin sensitivity were reported with the two diets, the investigators noted that total fat mass was significantly lower, and lean body mass was higher with the lower-GI diet. These very small, short duration studies cannot provide more than very weak support for the role of low GI diets in reducing CHD risk factors.",
"   </p>",
"   <p>",
"    Beneficial effects on CHD risk factors were also observed in several randomized trials examining effects of Mediterranean, low-glycemic load diets on lipids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/76\">",
"     76",
"    </a>",
"    ], as well as the components of the metabolic syndrome, including waist circumference, systolic and diastolic blood pressure, and triglycerides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/77\">",
"     77",
"    </a>",
"    ]. These studies did not examine the specific effects of low GI diets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperinsulinemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    insulin resistance may influence carcinogenesis. In the mid-1990s, it was noted that dietary and lifestyle risk factors for developing insulin resistance, such as physical inactivity, obesity, and positive energy balance, were also risk factors for developing colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. A high-glycemic index (GI) and low-fiber diet may lead to (or interact with) the state of insulin resistance such as hyperinsulinemia, hyperglycemia, and hypertriglyceridemia in influencing the carcinogenesis of colorectal cancer (CRC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least three case-control studies and two prospective cohort studies have examined the direct association between dietary GI and glycemic load (GL) with CRC risk.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A hospital-based, case-control study of colorectal cancer in Italian men and women reported an OR of 1.8 (95% CI 1.5-2.2) comparing extreme quintiles of GL; the corresponding OR for GI was 1.7 (95% CI 1.4-2.0) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A population-based, case-control study in the United States examined dietary GI and colon cancer and reported an OR for women of 1.34 comparing extreme quintiles (95% CI 1.00-1.81) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Swiss hospital-based, case-control study, an OR of 1.82 (95% CI 1.19-2.78) was reported for men and women combined, comparing extreme tertiles of GI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Women's Health Study found positive associations between dietary GL and overall GI and CRC incidence in this cohort of 39,876 women who were 45 years of age or older at baseline and followed for nearly eight years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a prospective study in Canadian women found no association between GL and total CRC (RR 1.05, 95% CI 0.73-1.53), although a sub-site analysis revealed an increased risk when restricted to the distal colon (corresponding RR 2.05, 95% CI 0.97-4.29) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/86\">",
"       86",
"      </a>",
"      ]. While high body mass index (BMI) and physical inactivity, factors that are related to insulin resistance, also appeared to increase the risk associated with a high-GL diet, the risk estimates lacked precision because of the limited number of cases (approximately 174) in this study.",
"     </li>",
"     <li>",
"      A large, prospective study among 73,061 Chinese women in the Shanghai Women's Health Study reported no significant association of overall glycemic index and glycemic load to CRC risk (multivariable hazard ratio for the highest versus lowest quintile of dietary GL 0.94, 95% CI 0.71-1.24) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relations of GI and GL with the risk of other cancers have not been extensively examined in prospective studies. One prospective study linked dietary GL to increased risk of pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/88\">",
"     88",
"    </a>",
"    ], while two others failed to show any association with breast cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. There are few data examining the possible link to prostate cancer, but in a study of 52,000 men, there was little relation between intakes of GI, GL, fiber and whole grain, and risk of this cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIETARY SOURCES OF CARBOHYDRATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevalence estimates from a 1994 to 1996 US Department of Agriculture survey indicated that only 3 percent of the population was consuming three or more servings of vegetables daily, and the mean intake of whole grains was less than one serving per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. To some extent, the public health campaign to lower fat in the United States has been translated by food manufacturers and consumers into a potentially harmful set of food choices. Instead of replacing high-fat foods with fruits, vegetables, legumes, and whole grain foods, consumers have often increased their consumption of low-fat or \"fat-free\" varieties of naturally high-fat foods, such as fat-free snack foods. The result is often an increase in high-glycemic load (GL) refined carbohydrates and sugar.",
"   </p>",
"   <p>",
"    The prevailing dietary pattern of the United States in the late 20",
"    <sup>",
"     th",
"    </sup>",
"    and early 21",
"    <sup>",
"     st",
"    </sup>",
"    century mainly consists of white bread, white rice, potatoes, soda, and sugar-laden snacks. The US food supply has become reliant on highly refined carbohydrates as significant sources of energy, since these carbohydrate-dense foods are economical and easily consumed in fast food restaurants or otherwise highly processed and prepackaged. The quality of these carbohydrates is considerably different from those consumed before the beginning of the 20",
"    <sup>",
"     th",
"    </sup>",
"    century, since the refining process has changed their compositions. As an example, processing whole grains into white flour actually increases the caloric density by 10 percent, reduces the amount of dietary fiber by 80 percent, and reduces the amount of dietary protein by almost 30 percent, leaving a dietary substance that is nearly pure starchy carbohydrate with fewer nutrients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The table lists the glycemic indices (GIs) for some major carbohydrate-contributing foods consumed by participants in the Nurses' Health Study, the GL values per serving, and their percent contribution to overall dietary GL (",
"    <a class=\"graphic graphic_table graphicRef71978 \" href=\"mobipreview.htm?8/40/8845\">",
"     table 1",
"    </a>",
"    ). There are now a variety of low-GI foods available to implement a low-GI diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/27\">",
"     27",
"    </a>",
"    ]. Using a standardized in vivo testing methodology endorsed by the WHO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/28\">",
"     28",
"    </a>",
"    ], researchers around the world continue to identify low-GI foods. A useful resource is",
"    <a class=\"external\" href=\"file://www.glycemicindex.com/\">",
"     www.glycemicindex.com",
"    </a>",
"    . This site allows the user to enter many different foods and determine both the GI and GL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Fructose",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United State, high fructose corn syrup sweeteners were not commercially available until 1960s, but now comprise more than 20 percent of total daily carbohydrate intake and 10 percent of daily total energy intake, representing an increase of more than 2100 percent. These sweeteners have surpassed sucrose as the leading sweetener in the US food industry, especially for soft drinks, accounting for much of the rebound increase in carbohydrate consumption after the mid-1960s, largely replacing the losses due to whole grains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9610?source=see_link&amp;anchor=H19#H19\">",
"     \"Risk factors for type 2 diabetes mellitus\", section on 'Sugar-sweetened beverages'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3418?source=see_link&amp;anchor=H14#H14\">",
"     \"Etiology and natural history of obesity\", section on 'Diet'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dominant type of high-fructose corn syrup now commercially available contains 55 percent fructose and 45 percent glucose, a chemical composition similar to sucrose. In an ecological assessment of national data between 1909 and 1997, Gross et al. found that intake of corn syrup increased by 2100 percent and fiber intake decreased by 40 percent, paralleling the upward trend of obesity and diabetes prevalence in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In theory, enzyme-catalyzed isomerization of dextrose to fructose (in making high-fructose corn syrup) may be physiologically different from that of sucrose (which is not broken down until it reaches the gut). Available evidence indicates that high intake of sugar-sweetened foods in general contribute to weight gain due to their relatively high energy density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/94\">",
"     94",
"    </a>",
"    ], glycemic load [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/95\">",
"     95",
"    </a>",
"    ], and palatability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/96\">",
"     96",
"    </a>",
"    ] (in comparison to high-fiber and low glycemic index foods). Moreover, these sugar-sweetened foods are frequently consumed in liquid rather than solid forms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/97\">",
"     97",
"    </a>",
"    ]. Although the specific metabolic effects of fructose on weight gain and insulin resistance have been reported, human data as yet are still mixed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38649/abstract/98-101\">",
"     98-101",
"    </a>",
"    ]. Thus, until there is more definitive data comparing the effects of high-fructose corn syrup with sucrose on both weight and cardiovascular health, it seems prudent to reduce the total consumption of these forms of sugar. Further, there is no good evidence that replacing high-fructose corn sweetener with sucrose will have any health benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/42/35490?source=see_link\">",
"       \"Patient information: Counting carbs if you do not use insulin (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current dietary recommendations emphasize the quantity of carbohydrates rather than their quality, despite the fact that carbohydrate source and nature profoundly affect postprandial glycemia. It is now well-established that even when foods contain the same amount of carbohydrate, there are clinically significant differences in glycemic effects. These differences led to the development of the concepts of glycemic index (GI) and glycemic load (GL). Although not all studies are in complete agreement and further research is clearly needed, the preponderance of the evidence supports the clinical utility of these nutritional concepts (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Glycemic index'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Glycemic load'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glycemic index is an in vivo measure of the relative impact of carbohydrate-containing foods on blood glucose.",
"     </li>",
"     <li>",
"      Glycemic load is the product of the GI value of a food and its carbohydrate content. The concept of the GL was developed in response to concerns that the GI cannot capture the entire glucose-raising potential of dietary carbohydrates because the blood glucose response is influenced not only by the quality of the carbohydrate consumed (ie, the GI), but also by the quantity of carbohydrate consumed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The GI and GL of several foods are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef71978 \" href=\"mobipreview.htm?8/40/8845\">",
"     table 1",
"    </a>",
"    ). Another useful resource is",
"    <a class=\"external\" href=\"file://www.glycemicindex.com/\">",
"     www.glycemicindex.com",
"    </a>",
"    . This site allows the user to enter many different foods and determine both the GI and GL. It also has general suggestions for maintaining a",
"    <span class=\"nowrap\">",
"     low-GI/GL",
"    </span>",
"    diet.",
"   </p>",
"   <p>",
"    The following values are generally applied for defining the GI of a particular food:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low GI &ndash; 55 or less",
"     </li>",
"     <li>",
"      Medium GI &ndash; 56 to 69",
"     </li>",
"     <li>",
"      High GI &ndash; 70 or more",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following values are generally applied for defining the GL of a particular food:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low GL &ndash; 10 or less",
"     </li>",
"     <li>",
"      Medium GL &ndash; 11 to 19",
"     </li>",
"     <li>",
"      High GL &ndash; 20 or more",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following values are generally applied for defining the GL per day:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low GL &ndash; Less than 80",
"     </li>",
"     <li>",
"      High GL &ndash; More than 120",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several prospective observational studies have associated diets high in GI and GL with risk of developing type 2 diabetes mellitus (DM), coronary heart disease (CHD), and some cancers. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Dietary carbohydrates and disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are several means to achieve a lower dietary GL:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Replace carbohydrate with protein",
"     </li>",
"     <li>",
"      Replace carbohydrate with fat",
"     </li>",
"     <li>",
"      Substitute a low-GI carbohydrate for a high-GI carbohydrate",
"     </li>",
"     <li>",
"      Combine all three methods",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Precisely which strategy would work best for healthy weight control and reduction in risk of type 2 DM and CHD remains uncertain. Nevertheless, available evidence is in support of an overall low-GL diet in which carbohydrate sources are mainly comprised of fruits, vegetables, and whole grains, with low consumption of flour-based products, such as bread and other baked products, and potatoes. Sugar-sweetened beverages should be consumed at most occasionally, and 100 percent fruit juices should be limited to not more than one small glass per day if at all. These dietary approaches to risk reduction may be particularly effective among the most susceptible individuals, those who are already overweight and insulin resistant.",
"   </p>",
"   <p>",
"    Patients should be reminded that healthy choices for fat (mono- and polyunsaturated fats) and protein (fish, nuts, legumes, and poultry) are encouraged because of the association between type of dietary fat and risk of CHD and diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2601?source=see_link\">",
"     \"Dietary fat\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\", section on 'Healthy diet'",
"    </a>",
"    .) Other elements of the diet, including vitamin supplements, may be important for other reasons. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31641?source=see_link\">",
"     \"Healthy diet in adults\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/1\">",
"      Gross LS, Li L, Ford ES, Liu S. Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr 2004; 79:774.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health. NIH Consensus Development Conference Statement on Diet and Exercise, US Department of Health and Human Services, Bethesda, MD 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/3\">",
"      American Diabetes Association, Bantle JP, Wylie-Rosett J, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008; 31 Suppl 1:S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/4\">",
"      Crapo PA, Reaven G, Olefsky J. Plasma glucose and insulin responses to orally administered simple and complex carbohydrates. Diabetes 1976; 25:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/5\">",
"      Crapo PA, Reaven G, Olefsky J. Postprandial plasma-glucose and -insulin responses to different complex carbohydrates. Diabetes 1977; 26:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/6\">",
"      Crapo PA, Kolterman OG, Waldeck N, et al. Postprandial hormonal responses to different types of complex carbohydrate in individuals with impaired glucose tolerance. Am J Clin Nutr 1980; 33:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/7\">",
"      Crapo PA, Insel J, Sperling M, Kolterman OG. Comparison of serum glucose, insulin, and glucagon responses to different types of complex carbohydrate in noninsulin-dependent diabetic patients. Am J Clin Nutr 1981; 34:184.",
"     </a>",
"    </li>",
"    <li>",
"     Wolever T. The glycemic index. In: Aspects of Some Vitamins, Minerals and Enzymes in Health and Disease, Bourne GH (Ed), Karger, Basel, Switzerland 1990. p.120.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/9\">",
"      Wolever, TM, Katzman-Relle, L, Jenkins, AL, et al. Glycemic index of 102 complex carbohydrate foods in patients with diabetes. Nutr Res 1994; 14:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/10\">",
"      Bantle JP. Clinical aspects of sucrose and fructose metabolism. Diabetes Care 1989; 12:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/11\">",
"      Lattimer JM, Haub MD. Effects of dietary fiber and its components on metabolic health. Nutrients 2010; 2:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/12\">",
"      Pan A, Hu FB. Effects of carbohydrates on satiety: differences between liquid and solid food. Curr Opin Clin Nutr Metab Care 2011; 14:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/13\">",
"      Jenkins DJ, Wolever TM, Taylor RH, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr 1981; 34:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/14\">",
"      Wolever TM, Jenkins DJ, Jenkins AL, Josse RG. The glycemic index: methodology and clinical implications. Am J Clin Nutr 1991; 54:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/15\">",
"      Wolever TM, Bolognesi C. Prediction of glucose and insulin responses of normal subjects after consuming mixed meals varying in energy, protein, fat, carbohydrate and glycemic index. J Nutr 1996; 126:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/16\">",
"      Brand JC, Nicholson PL, Thorburn AW, Truswell AS. Food processing and the glycemic index. Am J Clin Nutr 1985; 42:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/17\">",
"      Hallfrisch J, Behall KM. Mechanisms of the effects of grains on insulin and glucose responses. J Am Coll Nutr 2000; 19:320S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/18\">",
"      Hollenbeck CB, Coulston AM, Reaven GM. Glycemic effects of carbohydrates: a different perspective. Diabetes Care 1986; 9:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/19\">",
"      Ludwig DS. Clinical update: the low-glycaemic-index diet. Lancet 2007; 369:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/20\">",
"      Wolever TM. The glycemic index: flogging a dead horse? Diabetes Care 1997; 20:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/21\">",
"      Hollenbeck CB, Coulston AM, Reaven GM. Comparison of plasma glucose and insulin responses to mixed meals of high-, intermediate-, and low-glycemic potential. Diabetes Care 1988; 11:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/22\">",
"      Coulston AM, Hollenbeck CB, Liu GC, et al. Effect of source of dietary carbohydrate on plasma glucose, insulin, and gastric inhibitory polypeptide responses to test meals in subjects with noninsulin-dependent diabetes mellitus. Am J Clin Nutr 1984; 40:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/23\">",
"      Coulston AM, Hollenbeck CB, Swislocki AL, Reaven GM. Effect of source of dietary carbohydrate on plasma glucose and insulin responses to mixed meals in subjects with NIDDM. Diabetes Care 1987; 10:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/24\">",
"      Liu S, Manson JE. Dietary carbohydrates, physical inactivity, obesity, and the 'metabolic syndrome' as predictors of coronary heart disease. Curr Opin Lipidol 2001; 12:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/25\">",
"      Willett W, Manson J, Liu S. Glycemic index, glycemic load, and risk of type 2 diabetes. Am J Clin Nutr 2002; 76:274S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/26\">",
"      Liu S, Willett WC. Dietary glycemic load and atherothrombotic risk. Curr Atheroscler Rep 2002; 4:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/27\">",
"      Foster-Powell K, Holt SH, Brand-Miller JC. International table of glycemic index and glycemic load values: 2002. Am J Clin Nutr 2002; 76:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/28\">",
"      Wolever TM, Vorster HH, Bj&ouml;rck I, et al. Determination of the glycaemic index of foods: interlaboratory study. Eur J Clin Nutr 2003; 57:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/29\">",
"      Coulston AM, Reaven GM. Much ado about (almost) nothing. Diabetes Care 1997; 20:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/30\">",
"      Liu, S. Insulin resistance, hyperglycemia and risk of major chronic diseases -- a dietary perspective. Proceedings of the Nutrition Society of Australia 1998; 22:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/31\">",
"      Liu S, Willett WC, Stampfer MJ, et al. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr 2000; 71:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/32\">",
"      Englyst KN, Englyst HN, Hudson GJ, et al. Rapidly available glucose in foods: an in vitro measurement that reflects the glycemic response. Am J Clin Nutr 1999; 69:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/33\">",
"      Englyst KN, Vinoy S, Englyst HN, Lang V. Glycaemic index of cereal products explained by their content of rapidly and slowly available glucose. Br J Nutr 2003; 89:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/34\">",
"      Liu S. Intake of refined carbohydrates and whole grain foods in relation to risk of type 2 diabetes mellitus and coronary heart disease. J Am Coll Nutr 2002; 21:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/35\">",
"      Liu S, Willett WC, Manson JE, et al. Relation between changes in intakes of dietary fiber and grain products and changes in weight and development of obesity among middle-aged women. Am J Clin Nutr 2003; 78:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/36\">",
"      Pereira, M, Jacobs, D, Slattery, M, et al. The association of whole grain intake and fasting insulin in a biracial cohort of young adults: The CARDIA study. CVD Prevention 1998; 1:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/37\">",
"      McKeown NM, Meigs JB, Liu S, et al. Whole-grain intake is favorably associated with metabolic risk factors for type 2 diabetes and cardiovascular disease in the Framingham Offspring Study. Am J Clin Nutr 2002; 76:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/38\">",
"      Mozaffarian D, Hao T, Rimm EB, et al. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 2011; 364:2392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/39\">",
"      Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA 2002; 287:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/40\">",
"      Pereira MA, Swain J, Goldfine AB, et al. Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss. JAMA 2004; 292:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/41\">",
"      Ludwig DS. Dietary glycemic index and the regulation of body weight. Lipids 2003; 38:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/42\">",
"      Concei&ccedil;&atilde;o de Oliveira M, Sichieri R, Sanchez Moura A. Weight loss associated with a daily intake of three apples or three pears among overweight women. Nutrition 2003; 19:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/43\">",
"      McMillan-Price J, Petocz P, Atkinson F, et al. Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trial. Arch Intern Med 2006; 166:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/44\">",
"      Thomas DE, Elliott EJ, Baur L. Low glycaemic index or low glycaemic load diets for overweight and obesity. Cochrane Database Syst Rev 2007; :CD005105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/45\">",
"      Ebbeling CB, Leidig MM, Feldman HA, et al. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. JAMA 2007; 297:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/46\">",
"      Barclay AW, Petocz P, McMillan-Price J, et al. Glycemic index, glycemic load, and chronic disease risk--a meta-analysis of observational studies. Am J Clin Nutr 2008; 87:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/47\">",
"      Liu S, Chou EL. Dietary glycemic load and type 2 diabetes: modeling the glucose-raising potential of carbohydrates for prevention. Am J Clin Nutr 2010; 92:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/48\">",
"      Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994; 43:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/49\">",
"      DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/50\">",
"      Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/51\">",
"      Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992; 15:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/52\">",
"      Daly ME, Vale C, Walker M, et al. Dietary carbohydrates and insulin sensitivity: a review of the evidence and clinical implications. Am J Clin Nutr 1997; 66:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/53\">",
"      Pawlak DB, Kushner JA, Ludwig DS. Effects of dietary glycaemic index on adiposity, glucose homoeostasis, and plasma lipids in animals. Lancet 2004; 364:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/54\">",
"      Janket SJ, Manson JE, Sesso H, et al. A prospective study of sugar intake and risk of type 2 diabetes in women. Diabetes Care 2003; 26:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/55\">",
"      Wolever TM. The glycemic index. World Rev Nutr Diet 1990; 62:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/56\">",
"      Ebbeling CB, Ludwig DS. Treating obesity in youth: should dietary glycemic load be a consideration? Adv Pediatr 2001; 48:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/57\">",
"      Pereira, M, Jacobs, D, Pins, J, et al. The effect of whole grains on body weight and insulin sensitivity in overweight hyperinsulinemic adults. Diabetes 2000; 44:A40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/58\">",
"      Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2003; 26:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/59\">",
"      Thomas D, Elliott EJ. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. Cochrane Database Syst Rev 2009; :CD006296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/60\">",
"      DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/61\">",
"      Nathan DM. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002; 347:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/62\">",
"      Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/63\">",
"      Jeppesen J, Schaaf P, Jones C, et al. Effects of low-fat, high-carbohydrate diets on risk factors for ischemic heart disease in postmenopausal women. Am J Clin Nutr 1997; 65:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/64\">",
"      Abbasi F, McLaughlin T, Lamendola C, et al. High carbohydrate diets, triglyceride-rich lipoproteins, and coronary heart disease risk. Am J Cardiol 2000; 85:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/65\">",
"      Nestel PJ, Carroll KF, Havenstein N. Plasma triglyceride response to carbohydrates, fats and caloric intake. Metabolism 1970; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/66\">",
"      Mancini M, Mattock M, Rabaya E, et al. Studies of the mechanisms of carbohydrate-induced lipaemia in normal man. Atherosclerosis 1973; 17:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/67\">",
"      Hudgins LC, Seidman CE, Diakun J, Hirsch J. Human fatty acid synthesis is reduced after the substitution of dietary starch for sugar. Am J Clin Nutr 1998; 67:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/68\">",
"      Aarsland A, Chinkes D, Wolfe RR. Hepatic and whole-body fat synthesis in humans during carbohydrate overfeeding. Am J Clin Nutr 1997; 65:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/69\">",
"      Halton TL, Willett WC, Liu S, et al. Low-carbohydrate-diet score and the risk of coronary heart disease in women. N Engl J Med 2006; 355:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/70\">",
"      Liu S, Manson JE, Buring JE, et al. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 2002; 75:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/71\">",
"      Shikany JM, Tinker LF, Neuhouser ML, et al. Association of glycemic load with cardiovascular disease risk factors: the Women's Health Initiative Observational Study. Nutrition 2010; 26:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/72\">",
"      Mirrahimi A, de Souza RJ, Chiavaroli L, et al. Associations of glycemic index and load with coronary heart disease events: a systematic review and meta-analysis of prospective cohorts. J Am Heart Assoc 2012; 1:e000752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/73\">",
"      Oh K, Hu FB, Cho E, et al. Carbohydrate intake, glycemic index, glycemic load, and dietary fiber in relation to risk of stroke in women. Am J Epidemiol 2005; 161:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/74\">",
"      Dumesnil JG, Turgeon J, Tremblay A, et al. Effect of a low-glycaemic index--low-fat--high protein diet on the atherogenic metabolic risk profile of abdominally obese men. Br J Nutr 2001; 86:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/75\">",
"      Bouch&eacute; C, Rizkalla SW, Luo J, et al. Five-week, low-glycemic index diet decreases total fat mass and improves plasma lipid profile in moderately overweight nondiabetic men. Diabetes Care 2002; 25:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/76\">",
"      Jones JL, Comperatore M, Barona J, et al. A Mediterranean-style, low-glycemic-load diet decreases atherogenic lipoproteins and reduces lipoprotein (a) and oxidized low-density lipoprotein in women with metabolic syndrome. Metabolism 2012; 61:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/77\">",
"      Jones JL, Fernandez ML, McIntosh MS, et al. A Mediterranean-style low-glycemic-load diet improves variables of metabolic syndrome in women, and addition of a phytochemical-rich medical food enhances benefits on lipoprotein metabolism. J Clin Lipidol 2011; 5:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/78\">",
"      Giovannucci E. Insulin and colon cancer. Cancer Causes Control 1995; 6:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/79\">",
"      McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 1994; 3:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/80\">",
"      Bruce WR, Wolever TM, Giacca A. Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. Nutr Cancer 2000; 37:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/81\">",
"      Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001; 131:3109S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/82\">",
"      Franceschi S, Dal Maso L, Augustin L, et al. Dietary glycemic load and colorectal cancer risk. Ann Oncol 2001; 12:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/83\">",
"      Slattery ML, Benson J, Berry TD, et al. Dietary sugar and colon cancer. Cancer Epidemiol Biomarkers Prev 1997; 6:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/84\">",
"      Levi F, Pasche C, Lucchini F, et al. Glycaemic index, breast and colorectal cancer. Ann Oncol 2002; 13:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/85\">",
"      Higginbotham S, Zhang ZF, Lee IM, et al. Dietary glycemic load and risk of colorectal cancer in the Women's Health Study. J Natl Cancer Inst 2004; 96:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/86\">",
"      Terry PD, Jain M, Miller AB, et al. Glycemic load, carbohydrate intake, and risk of colorectal cancer in women: a prospective cohort study. J Natl Cancer Inst 2003; 95:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/87\">",
"      Li HL, Yang G, Shu XO, et al. Dietary glycemic load and risk of colorectal cancer in Chinese women. Am J Clin Nutr 2011; 93:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/88\">",
"      Michaud DS, Liu S, Giovannucci E, et al. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J Natl Cancer Inst 2002; 94:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/89\">",
"      Holmes MD, Liu S, Hankinson SE, et al. Dietary carbohydrates, fiber, and breast cancer risk. Am J Epidemiol 2004; 159:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/90\">",
"      Higginbotham S, Zhang ZF, Lee IM, et al. Dietary glycemic load and breast cancer risk in the Women's Health Study. Cancer Epidemiol Biomarkers Prev 2004; 13:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/91\">",
"      Nimptsch K, Kenfield S, Jensen MK, et al. Dietary glycemic index, glycemic load, insulin index, fiber and whole-grain intake in relation to risk of prostate cancer. Cancer Causes Control 2011; 22:51.",
"     </a>",
"    </li>",
"    <li>",
"     Putnam, J, Gerrior, S. Trends in the U.S. food supply, 1970-1997. In: America's Eating Habits: Changes and Consequences, Fraz&atilde;o, E (Ed), Economic Research Service, U.S. Department of Agriculture, Washington, DC 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/93\">",
"      Kantor LS, Variyam JN, Allshouse JE, et al. Choose a variety of grains daily, especially whole grains: a challenge for consumers. J Nutr 2001; 131:473S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/94\">",
"      Poppitt SD, Prentice AM. Energy density and its role in the control of food intake: evidence from metabolic and community studies. Appetite 1996; 26:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/95\">",
"      Liu S. Lowering dietary glycemic load for weight control and cardiovascular health: a matter of quality. Arch Intern Med 2006; 166:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/96\">",
"      Raben A, Macdonald I, Astrup A. Replacement of dietary fat by sucrose or starch: effects on 14 d ad libitum energy intake, energy expenditure and body weight in formerly obese and never-obese subjects. Int J Obes Relat Metab Disord 1997; 21:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/97\">",
"      Mattes RD. Dietary compensation by humans for supplemental energy provided as ethanol or carbohydrate in fluids. Physiol Behav 1996; 59:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/98\">",
"      Elliott SS, Keim NL, Stern JS, et al. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 2002; 76:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/99\">",
"      Teff KL, Grudziak J, Townsend RR, et al. Endocrine and metabolic effects of consuming fructose- and glucose-sweetened beverages with meals in obese men and women: influence of insulin resistance on plasma triglyceride responses. J Clin Endocrinol Metab 2009; 94:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/100\">",
"      Raben A, Vasilaras TH, M&oslash;ller AC, Astrup A. Sucrose compared with artificial sweeteners: different effects on ad libitum food intake and body weight after 10 wk of supplementation in overweight subjects. Am J Clin Nutr 2002; 76:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38649/abstract/101\">",
"      Sievenpiper JL, de Souza RJ, Mirrahimi A, et al. Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis. Ann Intern Med 2012; 156:291.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5374 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38649=[""].join("\n");
var outline_f37_47_38649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF CARBOHYDRATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GLYCEMIC INDEX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Determination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Utility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Mixed meals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Long-term data",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GLYCEMIC LOAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIETARY CARBOHYDRATES AND WEIGHT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Grains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effect of glycemic index/glycemic load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Very low carbohydrate diets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIETARY CARBOHYDRATES AND DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diabetes and metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIETARY SOURCES OF CARBOHYDRATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Fructose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/5374\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/5374|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/40/8845\" title=\"table 1\">",
"      Glycemic index and load values",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2601?source=related_link\">",
"      Dietary fat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3418?source=related_link\">",
"      Etiology and natural history of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/18/14634?source=related_link\">",
"      Nutritional considerations in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/42/35490?source=related_link\">",
"      Patient information: Counting carbs if you do not use insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9610?source=related_link\">",
"      Risk factors for type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_47_38650="Local treatment for primary soft tissue sarcoma of the extremities and chest wall";
var content_f37_47_38650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Local treatment for primary soft tissue sarcoma of the extremities and chest wall",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/47/38650/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38650/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38650/contributors\">",
"     David C Harmon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38650/contributors\">",
"     Mark C Gebhardt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/47/38650/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38650/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38650/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/47/38650/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38650/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/47/38650/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/47/38650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcomas are malignant tumors that arise from skeletal and extraskeletal connective tissues, including the peripheral nervous system. They can arise from mesenchymal tissue at any body site. Soft tissue sarcomas are uncommon. In the United States, approximately 11,410 cases are diagnosed annually, representing less than 1 percent of all newly diagnosed malignant tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Local treatment for primary soft tissue sarcoma (STS) of the extremities and chest wall will be reviewed here. Issues relating to classification, diagnosis, and staging of STS, the use of adjuvant and neoadjuvant chemotherapy, the treatment of STS in locations other than the extremities and chest wall, and treatment of locally recurrent and locally advanced unresectable STS of the extremities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14521?source=see_link\">",
"     \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=see_link\">",
"     \"Head and neck sarcomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=see_link\">",
"     \"Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27354?source=see_link\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7790646\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF MULTIDISCIPLINARY EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of their rarity and the frequent need for multimodality treatment, evaluation and management of soft tissue sarcomas should ideally be carried out in a center with expertise in the treatment of sarcomas, including surgical, orthopedic, medical, pediatric, and radiation oncology. The multidisciplinary team approach to care of soft tissue sarcomas optimizes treatment planning, minimizes duplication of diagnostic studies, and reduces the time to implementation of the definitive therapeutic protocol.",
"   </p>",
"   <p>",
"    Moreover, the expertise gained by dedicated subspecialists improves clinical outcomes. This was illustrated by one study that examined outcomes of 375 patients with soft tissue sarcoma of the extremities and torso according to the time of referral to a tumor center in the South Sweden Health Care Region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/2\">",
"     2",
"    </a>",
"    ]. Compared to patients referred preoperatively, local recurrence rates were 2.4-fold higher in patients not referred at any time and 1.3-fold higher in those referred only after definitive surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXTREMITY SARCOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In treating extremity STS, the major therapeutic goals are survival, avoidance of a local recurrence, maximizing function, and minimizing morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection of the primary tumor (total en bloc excision of the primary tumor without cutting into tumor tissue) is the essential component of treatment for virtually all patients. The resection should take place through tissues outside of the tumor pseudocapsule, if one exists, through normal uninvolved tissue. Violation of the tumor, ie, intralesional surgery or a resection that results in gross or microscopical residual tumor, is associated with a higher local failure rate. In one report, for example, the local control rate in 95 patients with extremity STS treated with preoperative radiation therapy followed by resection was 47 versus 87 percent in patients with and without tumor violation, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Periosteal stripping should be avoided, if possible, because it increases the risk of a later radiation-related pathologic fracture, particularly of the femur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/4\">",
"     4",
"    </a>",
"    ]. Resection of periosteum should be limited to those cases where tumor is abutting the periosteum.",
"   </p>",
"   <p>",
"    As with primary treatment, the goal of the surgical resection should be to widely resect the tumor with negative margins, meaning a cuff of normal tissue completely surrounding the tumor. The amount (thickness) of the uninvolved tissue necessary is debatable (traditionally 1 cm margins were recommended) and the assessment of the margin is difficult at best when the specimen leaves the wound. One cm margins seldom occur in reality and it is generally accepted that the type of tissue is important: thinner (1 to 2 mm) margins of fascia are likely adequate, whereas wider margins that consist of fat or muscle are suggested.",
"   </p>",
"   <p>",
"    Major nerves can often be preserved if they are carefully resected from the tumor, leaving the nerve sheath as a margin as it is rare that a nerve is actually invaded by tumor, but if so, it is necessary to resect the nerve in continuity with the tumor. Nerve grafts are seldom useful in the lower extremity in adults, especially in a radiated field, but may be successful in children. Function is still possible with complete resection of the sciatic nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/5\">",
"     5",
"    </a>",
"    ]. The patient will need to use an ankle-foot orthosis and extreme care in protecting the plantar skin to avoid pressure ulcers since protective sensation will be lost. Major arteries such as the superficial femoral artery can be excised if necessary to achieve negative margins and reconstructed with reverse saphenous vein grafts or artificial materials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/6\">",
"     6",
"    </a>",
"    ]. Reconstructing the vein is seldom successful and usually not necessary. In the upper extremity one tends to try to preserve the major nerves if at all possible, but if one of the nerves (median, ulnar or radial) requires resection, tendon transfers can be employed to restore some function.",
"   </p>",
"   <p>",
"    These surgical resections are more challenging in a previously irradiated field, and wound healing is challenging in this setting. Rotational flaps or free tissue transfers may be indicated. At times amputation may be the only reasonable alternative, or be necessary if there is a major complication. With modern prosthetics, many patients can function quite well depending on the level of the amputation, their age and comorbidities, and it should not always be considered a \"defeat\".",
"   </p>",
"   <p>",
"    Local recurrence rates after simple excision alone (ie, removal of the gross lesion with only a narrow margin of normal tissue) are 60 to 90 percent. In contrast, radical resection of a wider margin of apparently normal tissue around the tumor reduces the local failure rate to between 8 and 30 percent (",
"    <a class=\"graphic graphic_table graphicRef56886 \" href=\"mobipreview.htm?6/41/6812\">",
"     table 1",
"    </a>",
"    ). Following more radical surgery, such as a compartmental resection, local failure rates are between 10 and 20 percent. We reserve surgical excision alone for patients with superficial tumors that are 5 cm or less in diameter, as well as carefully selected patients with small purely intramuscular tumors, even if higher grade, provided that adequate surgical margins can be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Benefit of RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of limb-sparing surgery and radiation therapy achieves better local control than either modality alone for the majority of STS; however, no improvement in survival has been demonstrated. When combined with limb-sparing surgery, RT at moderate dose levels (50 to 65 Gy) can effectively eradicate microscopic disease extension beyond the gross lesion, resulting in rates of local control that are comparable to those achieved with amputation or radical surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, the use of adjuvant RT maximizes functional and cancer outcomes without the significant morbidity and cosmetic deformity of radical surgery. With combined therapy, most series report local control rates of approximately 85 to 90 percent for high-grade extremity STS and 90 to 100 percent for low-grade STS, depending upon size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/7-13\">",
"     7-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of adding RT to limb-sparing surgery has been addressed in two randomized trials, both of which showed that the combination of limb-sparing surgery and RT reduced the risk of local recurrence by 20 to 25 percent when compared to limb-sparing surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. While it is well documented that the risk of a local recurrence is higher for high-grade tumors, it is not uniformly low for low-grade tumors. In one of the randomized trials, the improvement in local control in irradiated patients appeared to be limited to patients with high-grade histopathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/14\">",
"     14",
"    </a>",
"    ], but in the other, there was a significant reduction in risk for low-grade tumors as well (5 versus 30 percent for patients treated with surgery alone) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/15\">",
"     15",
"    </a>",
"    ]. In neither trial did the reduction in local recurrence with RT translate into an overall survival advantage.",
"   </p>",
"   <p>",
"    Nevertheless, based upon these results as well as retrospective and population-based registry series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/16-21\">",
"     16-21",
"    </a>",
"    ], there appear to be some patients with low-grade extremity STS who do not require adjuvant RT. The identification of this subset remains challenging, in large part because of the difficulty in quantifying the risk of a local recurrence for individual patients based upon the usual features used to estimate prognosis such as size, depth, and histologic grade. A postoperative nomogram, which was based upon data from 684 patients with an extremity sarcoma treated with limb-sparing surgery alone at Memorial Sloan Kettering over a 24-year period, has been proposed to predict local recurrence rates at three and five years after limb-sparing surgery without RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/22\">",
"     22",
"    </a>",
"    ]. The nomogram includes five independent predictors of recurrence: age, size, margin status, grade, and histology. While this nomogram may be a useful tool to estimate the risk of a local recurrence in an individual patient, the appropriate cutoff point for deciding that the risk justifies the addition of RT is unclear. Furthermore, the nomogram has not been independently validated. &nbsp;",
"   </p>",
"   <p>",
"    We reserve surgical excision alone for patients with superficial, low-grade tumors that are 5 cm or less in diameter, as well as carefully selected patients with small purely intramuscular tumors, even if higher grade, provided that adequate surgical margins can be obtained. Some patients with larger, low-grade lesions such as well differentiated liposarcomas that are resected with wide margins may be considered for surgery alone. For all other patients, including those with low-grade histology, we advise RT in addition to surgery.",
"   </p>",
"   <p>",
"    The optimal timing of RT (ie, preoperative versus postoperative) is discussed in detail below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Preoperative versus postoperative RT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Limb salvage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to improving local control, adjuvant RT has also had a significant impact on rates of limb salvage for extremity STS. In the 1970s, up to one-half of patients with extremity STS underwent amputation. With the emergence of RT and advanced reconstructive techniques, the rate of amputation has been reduced to around 1 percent without any measurable fall in overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/7,23-27\">",
"     7,23-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    STS of the hand and foot tend to have a slightly better prognosis than do more proximal extremity STS. Five-year survival rates are approximately 80 percent, better than expected for proximal extremity STS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. With the use of adjunctive radiotherapy when the minimum surgical margin is narrow (less than 2 mm), limb amputation can be avoided as primary therapy in most patients, and up to two-thirds of patients can retain a normal or fairly normal extremity. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Functional outcome: limb salvage versus amputation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The current indications for primary amputation include massive disease such that a functional limb is not achievable, the need for resection of a major nerve such as the brachial plexus, or severely compromised normal tissues due to age, peripheral vascular disease, and other comorbidities. If required, standard amputations are used (eg, below-knee for foot lesions, above-knee for large calf lesions, and hip disarticulation for large proximal thigh lesions).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Functional outcome: limb salvage versus amputation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data suggest reasonable functional outcomes for patients undergoing limb salvage procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/24,31-34\">",
"     24,31-34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 88 patients treated with surgery and either preoperative or postoperative RT, 68 had acceptable functional results and 61 were able to return to work [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/24\">",
"       24",
"      </a>",
"      ].Large tumors, the need for neural sacrifice, proximal thigh tumors, and postoperative complications were associated with poor outcome.",
"     </li>",
"     <li>",
"      In a single institution report of 145 patients who underwent limb-sparing surgery plus postoperative RT, long term treatment-related complications included bone fracture in 6 percent, contracture in 20 percent, significant edema in 19 percent, moderate to severe decrease in muscle strength in 20 percent, requirement for a cane or crutch in 7 percent and tissue induration in 57 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/33\">",
"       33",
"      </a>",
"      ]. Three patients (2 percent) required an amputation for a treatment-related complication. Radiation and surgical techniques have improved considerably in the 20 years since that report. Nevertheless, the percentage of patients ambulating without assistive devices and with mild or no pain was 84 percent. Higher doses of RT, a long radiation portal, and irradiation of more than 75 percent of the extremity diameter were associated with more complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who require reconstruction to achieve wound closure do not appear to have worse long-term functional and health status outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Functional outcome is often not as good in patients requiring amputation. In a matched case-control study of patients with lower extremity sarcoma undergoing amputation (n = 12) or a limb-sparing approach (n = 24), there was a trend toward increased disability and handicap for those in the amputation group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/31\">",
"     31",
"    </a>",
"    ]. Seven of the 12 amputees reported ongoing problems with the soft tissue overlying the stump.",
"   </p>",
"   <p>",
"    A few studies have assessed quality of life issues in amputees who had been treated for STS with amputation and chemotherapy compared with patients who underwent limb salvage with RT and chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Contrary to expectations, there were no significant differences in measures of psychologic outcome. Thus, a psychologic advantage of limb-salvage surgery compared to amputation has yet to be demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Importance of margins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important surgical variable that influences local control is the status of the surgical margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/3,7,16,23,24,38-41\">",
"     3,7,16,23,24,38-41",
"    </a>",
"    ]. Although a positive margin by itself is not associated with a survival detriment, a positive surgical margin increases the risk of a local recurrence, which in turn, is a risk factor for distant metastasis and inferior survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/40,42\">",
"     40,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The status of the surgical margins influences the local recurrence rate even in patients treated with combined surgery and RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/38,41,43,44\">",
"     38,41,43,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 1225 patients, all of whom received combined surgery and RT (either preoperative, postoperative or both), local control rates at five years were 88, 76, and 64 percent for patients with negative, uncertain, and positive margins, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second report examined locoregional failure rates among 93 patients with a margin-positive resection following preoperative RT (50 Gy); 41 received a postoperative boost (16 Gy), while 52 did not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/43\">",
"       43",
"      </a>",
"      ]. The addition of a postoperative boost did not reduce the rate of local recurrence (22 versus 13 percent without a boost), or improve the five-year locoregional recurrence-free survival rate (74 versus 90 percent). Some of the patients who did not get the boost radiation underwent additional surgery to clear the involved margin or were felt to be at low risk for local recurrence with either well differentiated liposarcoma or a planned, focally positive margin. Thus, whether there is any benefit for a postoperative boost for a positive margin following 50 Gy remains uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, adjuvant RT at higher doses can improve the outcome in patients with positive margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The largest experience comes from a retrospective review of 154 patients with resected STS at any anatomic site (105 extremity, nine truncal), who had positive resection margins and who underwent RT with curative intent over a 31-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/44\">",
"     44",
"    </a>",
"    ]. At five years, rates of local control, disease-free survival, and overall survival for the entire cohort were 76, 47, and 65 percent, respectively. Outcomes were most favorable for patients with extremity primaries (five-year local control, disease-free and overall survival 82, 48, and 66 percent, respectively), those who received an RT dose &gt;64 Gy, and those who had microscopic (rather than grossly visible) margins, tumor size &lt;5 cm, and superficial rather than deep location. Among patients receiving RT doses &gt;64 Gy, 85 percent achieved local control at five years.",
"   </p>",
"   <p>",
"    Because local control is still worse with positive as compared to negative margins, reresection to negative margins is preferred if additional conservative surgery can be performed. However, reexcision must take into account the size of the reexcised field, the potential for damage or exposure of critical neurovascular structures necessitating reconstructive surgical procedures, and the fact that only a minority of margin-positive (R1) resections ever result in a local recurrence (30 percent in most series),&nbsp;whereas not all complete (R0) resections avoid recurrence (5 to 10 percent in most series). In major sarcoma centers, positive margins in patients with extremity lesions usually reflect tumor on the neurovascular bundle and further surgery to achieve negative margins would usually entail an amputation; most patients in this setting are treated with higher doses of adjuvant RT (in the range of 66-68 Gy) with amputation reserved for salvage.",
"   </p>",
"   <p>",
"    The exact width of the negative margin that is optimal for local control is not known. Most clinicians recommend that if surgery is used as the sole modality of treatment, the margin should be at least 1 cm in all directions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/46\">",
"     46",
"    </a>",
"    ] or include a fascial barrier. If surgery is combined with RT, the surgical margin can be safely reduced without compromising local control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/38\">",
"     38",
"    </a>",
"    ]. In one study of patients treated with preoperative RT followed by surgery for an extremity STS, local control rates were similar among patients with a negative margin of &le;1 or &gt;1 mm (96 versus 97 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/38\">",
"     38",
"    </a>",
"    ]. In a more recent study, no local failures were seen among 56 patients treated with preoperative computer-tomography planned RT if the surgical margins were &ge;1 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the majority of STS do not invade bone, it is seldom necessary to resect adjacent bone to achieve a negative margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In the absence of frank bone invasion, the periosteum is an adequate surgical margin for STS that are treated with wide excision and RT. However, resection of periosteum should be limited to those cases where tumor is abutting the periosteum because of the increased risk of pathologic fracture reported with periosteal resection.",
"   </p>",
"   <p>",
"    It is also rarely necessary to resect a major nerve unless the tumor is a neurogenic STS. Nonamputative surgery is now accomplished in more than 90 percent of patients; major centers do much better than this. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Limb salvage'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Management of the regional nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most adult-type STS have a &le;5 percent risk of lymph node metastases. The only exceptions are synovial sarcoma, the vascular sarcomas, rhabdomyosarcoma, and the epithelioid and clear cell subtypes, which have a higher risk of nodal metastases (11 to 44 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227107#H12227107\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Pattern of spread'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regional node dissection is usually only recommended if there is clinical or radiologic evidence of regional nodal disease.",
"   </p>",
"   <p>",
"    In most (but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/50\">",
"     50",
"    </a>",
"    ]) series, isolated nodal metastases do not carry the same dire prognosis as distant metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Some series report four to five year survival rates of 46 to 71 percent following lymphadenectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. As a result of these observations, regional nodal metastases were reclassified from stage IV to stage III disease in the 2010 modification of the TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef66617 \" href=\"mobipreview.htm?23/13/23773\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H351701269#H351701269\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sentinel lymph node biopsy (SLNB) has emerged as a reliable method of detecting occult nodal metastases in a variety of malignancies, including melanoma, breast, and penile cancer. For these cancers, the status of the SLN reflects the status of the nodal basin with 95 to 97 percent accuracy. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    For STS, particularly those types with a higher frequency of nodal involvement, it is unknown if earlier identification and treatment of occult nodal metastases using SLNB (followed by completion lymphadenectomy if the SLN is positive) would result in improved survival compared with lymphadenectomy only for clinically evident nodal metastases found by physical examination or radiologic imaging. The role of SLNB in patients with high-risk soft tissue sarcoma subtypes has been addressed in a few retrospective reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/55-60\">",
"     55-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest of these series, 29 patients with a nonmetastatic extremity STS associated with a high rate of nodal metastases (synovial, clear cell, angiosarcoma, rhabdomyosarcoma, epithelioid sarcoma) underwent SLNB along with resection of the primary tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/55\">",
"     55",
"    </a>",
"    ]. Among the 20 who had it, the preoperative staging PET scan was interpreted as negative in 16, indeterminate in three, and suspicious in one.",
"   </p>",
"   <p>",
"    At least one SLN was found in 28 patients (97 percent). Only one patient (who had a suspicious PET scan) had a positive SLN with micrometastatic disease on pathologic evaluation. He refused completion lymphadenectomy, and despite regional nodal irradiation, developed lung metastases. Two other patients had only immunohistochemical evidence of SLN involvement, and neither relapsed despite not having a completion lymphadenectomy. An additional patient with a negative SLNB later developed a nodal metastasis, and five other patients with a negative SLNB developed distant metastatic disease.",
"   </p>",
"   <p>",
"    The results of other smaller series and single case reports are mixed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. In many (but not all) cases, patients with positive SLNB have developed distant metastases despite therapeutic lymphadenectomy, and several SLN-negative patients have developed later metastatic disease.",
"   </p>",
"   <p>",
"    Taken together these data suggest that a positive SLNB does not necessarily imply future metastatic disease, nor does the removal of involved nodes by completion lymphadenectomy prevent later distant metastatic spread. Thus, the role of SLNB in this disease, even for histologies with a high rate of nodal spread, remains unclear.",
"   </p>",
"   <p>",
"    The role of PET in the staging of soft tissue sarcoma is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227163#H12227163\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'PET and PET/CT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Management of an initially incompletely resected primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;In planning primary therapy for a patient who has had an initial suboptimal resection (often by a nononcologic surgeon)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    insufficient preoperative imaging, reresection is preferred if possible, generally in conjunction with radiation given either before or after reresection. Approximately 37 to 68 percent of such patients will have residual tumor in the reresection specimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/25,61-64\">",
"     25,61-64",
"    </a>",
"    ]. Partial excision of the tumor before referral to a tertiary center does not appear to compromise limb preservation, local control, or, in most series, survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/25,64-67\">",
"     25,64-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a higher incidence of distant metastatic disease has been reported in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/68\">",
"     68",
"    </a>",
"    ], and reresection may entail a larger procedure than a de novo procedure and impact upon the functional result. These data underscore the importance of transferring patients with soft tissue masses of uncertain identify to centers that specialize in treating sarcomas so that they can undergo adequate initial resection.",
"   </p>",
"   <p>",
"    Some patients are not candidates for reresection, either because of a medical contraindication or the desire to preserve extremity function. The use of RT as an alternative to reresection can help secure local control in a substantial proportion of these patients. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Importance of margins'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Preoperative versus postoperative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive RT can be administered preoperatively (neoadjuvant RT) or postoperatively (adjuvant RT). There are potential advantages of both approaches. Preoperative RT might be expected to reduce tumor burden, theoretically allowing more conservative surgical therapy. Postoperative RT allows histologic examination of the tumor specimen and is also associated with fewer wound complications (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Wound healing after surgery and RT'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Retrospective uncontrolled series of patients who have received either postoperative or preoperative RT have reported local control and disease-specific survival rates that are at least as good with preoperative as compared to postoperative therapy RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/69-73\">",
"     69-73",
"    </a>",
"    ], and possibly better [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The only phase III clinical trial to evaluate this question was conducted in Canada, and randomly assigned 190 patients with primary (90 percent) or recurrent (10 percent) extremity STS (83 percent intermediate or high-grade) to either preoperative or postoperative RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/12\">",
"     12",
"    </a>",
"    ]. The 94 patients assigned to preoperative therapy all received 50 Gy prior to surgery with a postoperative boost (16 to 20 Gy) given to the 14 patients with a positive margin. All patients in the postoperative group received 50 Gy to the initial field plus a 16 to 20 Gy boost. Complications were defined as secondary wound surgery, hospital admission for wound care, or the need for deep packing or prolonged wound dressings within 120 days of tumor resection.",
"   </p>",
"   <p>",
"    The study was terminated when a highly significant result was obtained at the time of a planned interim analysis. With a median follow-up of 3.3 years, acute wound complications were significantly more common with preoperative treatment (35 versus 17 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/12\">",
"     12",
"    </a>",
"    ]. Other factors associated with acute wound complications were the volume of resected tissue and lower limb location of the tumor.",
"   </p>",
"   <p>",
"    In the latest update (median follow-up of 6.9 years), there was no difference in local control with preoperative versus postoperative RT, with over 90 percent of patients controlled locally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/76\">",
"     76",
"    </a>",
"    ]. The regional and distant failure rates as well as the progression-free and overall survival rates are also similar. However, patients treated postoperatively developed significantly more grade 2 to 4 late toxicity than those treated preoperatively (86 versus 68 percent, respectively). In particular, the incidence of grade 3 (severe induration and loss of subcutaneous tissue or field contracture &gt;10 percent linear measurement) or grade 4 (necrosis) subcutaneous fibrosis was significantly higher in the postoperative group (36 versus 23 percent, respectively).",
"   </p>",
"   <p>",
"    Although not statistically significant, limb edema (23 versus 16 percent) and joint stiffness (23 versus 18 percent) were both more common in the postoperative treatment group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/77\">",
"     77",
"    </a>",
"    ]. Fibrosis, edema and joint stiffness adversely affected functional outcomes.",
"   </p>",
"   <p>",
"    The Canadian study demonstrates that efficacy is similar using preoperative or postoperative RT, and that the higher rate of generally reversible acute wound healing complications in preoperatively treated patients is offset by a lower rate of generally irreversible late complications, including grade 3 to 4 fibrosis. Because very few acute wound-healing complications occurred in either group with tumors located in the upper extremity (a finding that is reported by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]), the authors suggested that these patients preferentially receive preoperative RT. However, we favor the preoperative approach for most patients with lower extremity sarcomas as well, given that acute wound complications can usually be managed and heal in the long run, while late treatment effects are generally irreversible.",
"   </p>",
"   <p>",
"    New strategies are needed for patients with lower extremity sarcomas to reduce the risk of acute wound healing problems when preoperative RT is administered, and to reduce the risk of late treatment induced effects when higher-dose, larger field post-operative RT is given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to external beam RT (EBRT), brachytherapy minimizes the radiation dose to surrounding normal tissues, maximizes the dose delivered to the tumor, and shortens treatment times. In the usual schedule, treatment is completed within six days and requires only one hospitalization. Afterloading catheters are placed in a target area of the tumor operative bed, defined by the surgeon, and spaced at 1 cm intervals to cover the entire area of risk.",
"   </p>",
"   <p>",
"    A phase III trial of postoperative brachytherapy (45 Gy) versus no brachytherapy was conducted in 164 patients who had complete resection of either an extremity or superficial trunk STS (45 low-grade, 119 high-grade) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/14\">",
"     14",
"    </a>",
"    ]. Five-year local control rates were 82 and 69 percent for the brachytherapy and surgery alone groups, respectively. The advantage of brachytherapy was seen only in the high-grade (local control 89 versus 66 percent) and not the low-grade subtypes. There was no difference between the groups in distant metastasis or disease-specific survival, regardless of histology.",
"   </p>",
"   <p>",
"    There have been no randomized comparisons of the relative efficacy or morbidity of EBRT compared with brachytherapy. Although it is unclear if brachytherapy is associated with a higher risk of wound complications, the rate of wound reoperation may be higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/80\">",
"     80",
"    </a>",
"    ]. Brachytherapy has been combined with free flap construction as a means of enhancing primary healing in difficult anatomic situations without an increase in the incidence of wound breakdown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Wound healing after surgery and RT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a retrospective comparison of patients treated by IMRT or brachytherapy, the IMRT group appeared to have somewhat worse prognostic features, but the five-year local control rate was significantly higher than in the brachytherapy group (92 versus 82 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Initial chemoradiotherapy for large high-grade STS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eilber initially popularized the combination of preoperative intraarterial chemotherapy plus RT followed by limb salvage surgery in patients with high-grade extremity STS. They were able to achieve a high rate of primary limb salvage, low local recurrence rates (approximately 9 percent) and long-term survival in 65 percent of patients.",
"   </p>",
"   <p>",
"    More recent efforts have explored administration of intravenous rather than intraarterial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    concurrent with preoperative RT, and the use of interdigitated RT with cycles of combination doxorubicin-containing chemotherapy regimens such as MAID (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    , doxorubicin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    , (",
"    <a class=\"graphic graphic_table graphicRef80881 \" href=\"mobipreview.htm?21/21/21854\">",
"     table 3",
"    </a>",
"    )). Whether the use of interdigitated MAID with RT provides better antitumor activity than other neoadjuvant approaches remains uncertain. When this approach was employed in an RTOG (Radiation Therapy Oncology Group) trial with higher ifosfamide doses and generous radiation fields (9 cm proximal and distal to gross tumor), high rates of early toxicity were seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/83\">",
"     83",
"    </a>",
"    ], although they mostly resolved within one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While some centers use concomitant chemoradiotherapy with single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , others prefer preoperative RT alone or sequential RT and doxorubicin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    -based chemotherapy, or RT combined with alternative chemotherapy agents (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ) for such patients. This subject is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27354?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\", section on 'Preoperative chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies that utilize neoadjuvant therapy also illustrate the problem of response assessment. In many of these studies, tumor size did not change much by examination or imaging after neoadjuvant therapy, while the degree of necrosis was substantial on histologic review of the surgical specimen. This finding, which is observed repeatedly in the treatment of sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/85,86\">",
"     85,86",
"    </a>",
"    ], refutes the utility of objective measures of disease response such as the RECIST (Response Evaluation Criteria in Solid Tumors (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"mobipreview.htm?41/48/42764\">",
"     table 4",
"    </a>",
"    )) or WHO criteria as the sole indicator of a clinical response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27354?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\", section on 'Response assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While some have suggested utility for fluorodeoxyglucose (FDG)-PET imaging as a means of identifying histopathologic treatment response as early as after one cycle of neoadjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/87-90\">",
"     87-90",
"    </a>",
"    ], prospective studies are needed to validate this approach. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     RT alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are medically inoperable or if a function-preserving resection is not possible and amputation is not accepted, RT alone is an effective treatment for STS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/91\">",
"     91",
"    </a>",
"    ]. The radiation sensitivity of cell lines derived from sarcomas is not less than that of epithelial cell lines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/92\">",
"     92",
"    </a>",
"    ]. Myxoid liposarcomas are a particularly radiosensitive subtype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For small sarcomas, good local control rates can be achieved by RT alone. However, local control probabilities of &gt;90 percent for tumors of estimated volume 15 to 65 mL (approximately a sphere of 3 to 5 cm in diameter) requires high RT doses (&gt;75 Gy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/24\">",
"     24",
"    </a>",
"    ]. As most treatment volumes are relatively large, the late normal tissue changes resulting from these dose levels are clinically important in nearly all patients. In animal models, a significantly lower RT dose is required to achieve local control when RT is combined with simple excision as compared to RT alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommended treatment for most patients with an extremity STS who are medically and technically operable is combined surgery and RT. In most instances, the probability of tumor control is higher, and the late functional and cosmetic result is clearly superior following combined modality therapy than with radical surgery alone.",
"   </p>",
"   <p>",
"    Exceptions include small (&lt; 5 cm), superficial STS which can be widely resected, particularly if they are low-grade, or purely intramuscular tumors; in these circumstances, surgery alone is appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/95-97\">",
"     95-97",
"    </a>",
"    ]. In addition, some low-grade well-differentiated liposarcomas may be managed initially with surgery alone, even if large and deep seated, if the location is one where it might be possible to safely reresect a local recurrence ten or twenty years later. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Benefit of RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We favor preoperative rather than postoperative radiotherapy for most patients with upper and lower extremity sarcomas, because acute wound complications, which occur more often with preoperative therapy, can usually be managed and heal in the long-run, while the late treatment effects (which are more common with postoperative therapy) are generally irreversible. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Preoperative versus postoperative RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Various neoadjuvant approaches have been used for patients with large, intermediate or high grade extremity lesions in an attempt to optimize limb salvage surgery and reduce the risk of distant metastases. The particular approach chosen (RT alone, RT combined with single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , sequential RT and chemotherapy) should be based upon institutional expertise, experience and preferences. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Initial chemoradiotherapy for large high-grade STS'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     NCCN guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus-based guidelines from the National Comprehensive Cancer Network for primary extremity STS can be summarized as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/98\">",
"     98",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low grade tumors &lt;5 cm, either superficial or deep &mdash; surgery with consideration of postoperative RT if the margins are &le;1 cm",
"     </li>",
"     <li>",
"      Low-grade tumors &gt;5 cm, either superficial or deep &mdash; surgery with postoperative RT for all patients with margins &le;1 cm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For high-grade tumors of any size, either superficial or deep, the treatment recommendations are based upon the assessment of resectability and functional outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For a tumor that is resectable with an acceptable functional outcome, options include surgery followed by RT, surgery alone (for small tumors resected with wide margins), preoperative RT, preoperative chemotherapy, or preoperative chemoradiotherapy.",
"     </li>",
"     <li>",
"      For a tumor that is potentially resectable but with concern for adverse functional outcomes, options include preoperative RT, preoperative chemotherapy, or preoperative chemoradiotherapy. The guidelines do not include a specific chemoradiotherapy regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CHEST WALL SARCOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary STS of the chest wall are rare, accounting for about 6 percent of all STS, and about one-half of all malignant tumors arising on the chest wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/99\">",
"     99",
"    </a>",
"    ]. The differential diagnosis of a chest wall STS is broad and benign tumors (fibrous dysplasia, chondroma, osteochondroma, aneurysmal bone cyst, Langerhans cell histiocytosis, desmoid, chondroblastoma, osteoblastoma) and other malignancies (chondrosarcoma, osteosarcoma, Ewings sarcoma family of tumors, solitary plasmacytoma). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=see_link\">",
"     \"Overview of benign bone tumors in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32551?source=see_link\">",
"     \"Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although patients often present with a mass or pain, some tumors are found incidentally on routine chest x-ray.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authors group these chest wall sarcomas with retroperitoneal and subcutaneous sarcomas, while others include them in the ill-defined term \"truncal sarcomas\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/100\">",
"     100",
"    </a>",
"    ]. However, the clinical behavior of chest wall sarcomas is more similar to extremity STS than to retroperitoneal STS (which, like head and neck sarcomas, have a poorer prognosis). Thus, they should be treated similarly to extremity sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/101-105\">",
"     101-105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wide local resection is the standard curative treatment with adjuvant radiotherapy employed for lesions resected with close or positive margins. Five-year overall survival rates are 63 to 89 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/101,104,105\">",
"     101,104,105",
"    </a>",
"    ]. Outcomes are less favorable with secondary (radiation-induced) sarcomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical resection is also the treatment of choice for locally recurrent tumors, although rates of local control are lower than that seen after primary resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of sarcomas arising in the breast is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27689?source=see_link\">",
"     \"Breast sarcoma: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     WOUND HEALING AFTER SURGERY AND RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the addition of RT to surgery increases the frequency of wound complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/12,106-109\">",
"     12,106-109",
"    </a>",
"    ]. Quantitation of the impact of RT on wound healing is difficult because of the significant complications seen with surgery alone. In addition, there is much heterogeneity among patients with STS with respect to anatomic site, histologic type, lesion size, prior surgery, medical status, and age. Wound healing is also affected by the extent of the surgical resection and variability in the amount and type of tissue removed at resection.",
"   </p>",
"   <p>",
"    The use of adjunctive RT can also be associated with joint stiffness, decreased limb strength, edema, and decreased range of motion, although symptoms are transient and do not affect global quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/15,71\">",
"     15,71",
"    </a>",
"    ]. The risk for complications with RT must be weighed against the potential morbidity resulting from locally recurrent tumor in patients treated with surgery alone, as well as the functional and cosmetic consequences if more radical surgery is performed when RT is omitted. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Benefit of RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Timing of RT and wound complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative RT is associated with a higher incidence of acute wound complications than seen with surgery alone or postoperative RT, particularly for lower extremity lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/12,110\">",
"     12,110",
"    </a>",
"    ]. However, compared to postoperative RT, lower doses (50 versus 60 to 66 Gy) and smaller field sizes can be used, and there is a reduced risk of late, often irreversible complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/12\">",
"     12",
"    </a>",
"    ]. These observations have led some to conclude that preoperative treatment is preferable, despite the higher rate of acute complications (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Preoperative versus postoperative RT'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Brachytherapy and wound complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the use of perioperative brachytherapy increases the incidence of wound complications is unclear; the data are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 105 patients with extremity and truncal STS, major wound complications occurred in substantially more patients treated with brachytherapy compared to non-brachytherapy-treated patients (9 of 41 versus 2 of 64 cases, 22 versus 3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/111\">",
"       111",
"      </a>",
"      ]. Patients treated with brachytherapy also had a higher total number of complications, a higher combined frequency of major and moderate wound complications (44 versus 14 percent), and a longer time to wound healing (189 versus 49 days).",
"     </li>",
"     <li>",
"      The findings were different in a randomized trial of adjuvant brachytherapy versus no brachytherapy in 164 patients with resected extremity or truncal STS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/80\">",
"       80",
"      </a>",
"      ]. The incidence of serious wound complications was not significantly increased in the group receiving brachytherapy (24 versus 14 percent, p = 0.133), but the incidence of wound reoperation was higher (6 versus 0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Strategies to reduce wound morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following strategies may help to reduce wound morbidity in patients being treated with preoperative RT or perioperative brachytherapy for soft tissue sarcoma (STS), although high level evidence to support these recommendations is lacking:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gentle handling of tissue during surgery.",
"     </li>",
"     <li>",
"      The use of contemporary prospectively planned reconstructive efforts with vascularized tissue flaps, which have reduced the incidence of serious wound healing issues to 3 to 5 percent in most (but not all [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/112\">",
"       112",
"      </a>",
"      ]) series.",
"     </li>",
"     <li>",
"      Meticulous attention to achieving hemostasis before wound closure.",
"     </li>",
"     <li>",
"      Avoidance of closure under tension.",
"     </li>",
"     <li>",
"      Minimizing wound dead space, using a rotational or free tissue muscle transfers to reduce dead space, if necessary.",
"     </li>",
"     <li>",
"      Wound drainage with tubes remaining in place until drainage is decreasing is usually advised, although there are few studies that document benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/113,114\">",
"       113,114",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of compression dressings may be helpful.",
"     </li>",
"     <li>",
"      Immobilization of the affected extremity until it is clear that there are no significant wound healing issues.",
"     </li>",
"     <li>",
"      Delineation of a subgroup of patients receiving radiation as a component of their therapy for whom a postoperative radiation boost dose can be omitted (eg, those with negative margins and no tumor cut-through, complete tumor necrosis, or absence of any residual tumor in the resection specimen).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who develop a perioperative wound complication, especially partial or total wound dehiscence, negative pressure wound therapy (NPWT) can facilitate wound healing and primary wound closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/115-117\">",
"     115-117",
"    </a>",
"    ]. By using controlled negative pressure, NPWT evacuates fluid, stimulates the formation of granulation tissue, and decreases bacterial colonization. The criteria used to select patients for NPWT versus some other type of wound management approach are not well defined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26264?source=see_link\">",
"     \"Negative pressure wound therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several prognostic factors have been identified for survival, as well as distant and local recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Tumor size, grade, and histologic subtype",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a review of prognostic factors in 1041 patients with extremity soft tissue sarcomas, tumor size and grade were the main predictors of distant recurrence and survival, while age over 50 and the presence of positive resection margins predicted for local recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/16\">",
"     16",
"    </a>",
"    ]. Specific histopathologic subtypes were associated with higher rates of local failure (fibrosarcoma and malignant peripheral nerve sheath tumor [MPNST]) and worse tumor-related survival (leiomyosarcoma [LMS] and MPNST).",
"   </p>",
"   <p>",
"    A worse prognosis for MPNST and angiosarcomas has been noted by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/27,118\">",
"     27,118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor stage as determined by the AJCC staging classification is of limited utility in estimating prognosis. Compared to the older 2002 version of the staging criteria (",
"    <a class=\"graphic graphic_table graphicRef69154 \" href=\"mobipreview.htm?10/30/10733\">",
"     table 5",
"    </a>",
"    ), the 2010 modification (",
"    <a class=\"graphic graphic_table graphicRef66617 \" href=\"mobipreview.htm?23/13/23773\">",
"     table 2",
"    </a>",
"    ) reclassified regional nodal involvement from stage IV to stage III disease. However, features of primary tumor classification in the 2002 edition were not maintained in the 2010 version. Specifically, the inclusion of both superficial and deep tumors within the same prognostic groups for tumors of the same size eliminates a criterion that previously stratified patient risk, without supporting data to suggest it is unnecessary.",
"   </p>",
"   <p>",
"    Because of this problem, we prefer the use of the 2002 version rather than the 2010 version, when the TNM system is used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H351701269#H351701269\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another problem shared by both the 2002 and the 2010 classifications is that sarcomas over 10 cm in size have a greater risk of recurrence than do those 5 to 10 cm in size; both editions only stratify primary tumor stage as &le;5 versus &gt;5 cm in size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22265690\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has long been a concern that older patients would have inferior outcomes because they present with larger, higher grade tumors, and tend to receive definitive surgery, chemotherapy, and RT less often [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/119-121\">",
"     119-121",
"    </a>",
"    ]. However, at least some data suggest that older patients have higher rates of local recurrence and distant metastases than do younger individuals and that the disparity cannot be entirely accounted for by worse tumor characteristics at presentation or less aggressive treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic grade, the presence or absence of metastatic disease, and achieving macroscopic total resection are the major determinants of survival. Nomograms, which incorporate these and other clinicopathologic features, have been developed to more accurately predict postoperative survival (",
"    <a class=\"graphic graphic_figure graphicRef80175 \" href=\"mobipreview.htm?4/37/4703\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/18,123-125\">",
"     18,123-125",
"    </a>",
"    ]. Some of these are available online (",
"    <a class=\"external\" href=\"file://www.mskcc.org/mskcc/html/6181.cfm\">",
"     Memorial Sloan Kettering Cancer Center sarcoma nomogram",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://www.prognomics.org/sam\">",
"     Helsinki University sarcoma nomogram",
"    </a>",
"    ). .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     RADIATION TREATMENT PLANNING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiation treatment technique should be carefully planned so that the tissues being irradiated are only those judged to be at risk. In order to utilize smaller treatment volumes, the part to be irradiated must be securely and reproducibly immobilized. We use special immobilization devices prepared for each individual patient. This may require casting, especially for hand, foot, or elbow sites. For some sites, the part is placed in standard plastic supports and the extremity fastened tightly in place using a velcro fastener. Others describe their experience with polyurethane foam systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The principal tasks involved in the development of a treatment plan for STS are to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Define the target volume (on each section of the",
"      <span class=\"nowrap\">",
"       CT/MRI",
"      </span>",
"      of the affected region).",
"     </li>",
"     <li>",
"      Define nontarget critical structures in the treatment volume and specify dose constraints for each such structure.",
"     </li>",
"     <li>",
"      Estimate the distribution of number of tumor",
"      <span class=\"nowrap\">",
"       clonogens/unit",
"      </span>",
"      volume of tissue throughout the target volume.",
"     </li>",
"     <li>",
"      Define a series of target volumes to realize the appropriate dose distribution using \"shrinking treatment volume methods\".",
"     </li>",
"     <li>",
"      Design an immobilization device and a means to assure that the target is on the beam.",
"     </li>",
"     <li>",
"      Design treatment techniques which achieve the closest feasible conformation of treatment to target volume.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For postoperative radiation, we use a \"shrinking treatment volume technique\" with a series of progressively smaller volumes, with the highest dose being administered to the tumor bed itself. Preoperative radiation is generally only delivered to a single clinical target volume (see below) for the majority of patients, with any additional radiation to a reduced field reserved for postoperative treatment of the small proportion of patients with a histologically positive margin. Three dimensional conformal RT (3D-CRT) treatment planning systems allow smaller and more accurate treatment volumes in patients with extremity STS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/127\">",
"     127",
"    </a>",
"    ]. These systems also allow image fusion with the MRI scans to better define the target volumes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Clinical target volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal clinical target volume (CTV) is debated. There are no data from controlled trials that address the appropriate CTV for patients with extremity or chest wall STS. Radiation fields traditionally included a generous longitudinal margin of 5 to 10 cm beyond the gross tumor. These fields were conceived in the era before the routine use of MRI (see below). The use of 5 cm proximal and distal margins and 2 cm radial margins for the first 50 Gy (on the tumor for preoperative RT and the surgical bed for postoperative therapy) provided very high rates of local control in the randomized NCI Canada trial discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Preoperative versus postoperative RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The radial margin should be viewed with respect to the direction of most likely spread; the margin can be 2 cm where there is bone, interosseous membrane, or major fascial planes, and imaging studies show these planes to be intact. When a fascial plane has been violated, the 2 cm rule no longer applies and wider margins are appropriate.",
"   </p>",
"   <p>",
"    The 2 cm radial margin rule is rationally derived from surgical experience. Local control rates are high when margins exceed 1 cm. The additional centimeter added to the RT margins allows for some daily set-up variation and the penumbra of the beam edge.",
"   </p>",
"   <p>",
"    Newer data on carefully selected patients treated with surgery alone shows excellent local control in cases with the closest histologically negative margin 1 cm or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/96\">",
"     96",
"    </a>",
"    ]. This has prompted interest in tailoring the CTV more closely to the distribution of microscopic residual tumor beyond the grossly visible tumor.",
"   </p>",
"   <p>",
"    The distribution of microscopic residual tumor was addressed in a study correlating MRI findings with histopathology of the resected specimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/96\">",
"     96",
"    </a>",
"    ]. Sarcoma cells were identified histologically in the tissues beyond the tumor in 10 of 15 cases. In six, tumor cells were located within 1 cm of the tumor margin, and in four cases, malignant cells were found at a distance &gt;1 cm and up to a maximum of 4 cm; in 9 of 10 cases, the tumor cells were located in areas of edema as imaged on T2-weighted MRI scans.",
"   </p>",
"   <p>",
"    Thus, MRI is increasingly being used to define the preoperative CTV. Patterns of local failure were studied in 56 patients treated with MRI-guided 3D-CRT field planning for extremity STS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/47\">",
"     47",
"    </a>",
"    ]. The CTV included the T1 post-gadolinium-defined gross tumor volume with 1- to 1.5-cm radial and 3.5-cm longitudinal margins. Planning target volume expansion was 5 to 7 mm, and &gt;95 percent of the dose was delivered to the planning target volume. The median preoperative RT dose was 50 Gy. Postoperative boost of 10 to 20 Gy was given to 12 patients (six with positive margins and six with close margins). Three patients (all with positive margins) experienced local failure as first relapse (two isolated, one with distant failure), and two additional patients (all with margin&lt;1 mm) had late local failure after distant metastasis. The local failures were within the CTV in three patients and within and also extending beyond the CTV in two. No local recurrences were observed in patients whose surgical margins were &gt;1 mm.",
"   </p>",
"   <p>",
"    Thus, these target volume definitions appear to be appropriate for most patients, although some patients with particularly infiltrative histologies such as some subcutaneous myxofibrosarcomas might require more generous margins.",
"   </p>",
"   <p>",
"    The RTOG study 0630, testing the use of even more constrained CTVs in the setting of image-guided preoperative RT, has recently completed accrual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/129\">",
"     129",
"    </a>",
"    ]. The CTV in that study encompassed gross tumor plus 2 cm margins (for tumors &lt;8 cm in size and 3 cm margins for tumors &gt;8 cm) in the longitudinal (proximal and distal) directions as well as any areas of suspicious edema (defined by MRI T2 images). If this caused the field to extend beyond the compartment, the field could be shortened to include the end of a compartment plus a margin of 1 cm. The radial margin from the lesion was 1.5 cm including any portion of the tumor not confined by an intact fascial barrier or uninvolved bone or skin surface. The results from this study are currently pending.",
"   </p>",
"   <p>",
"    A randomized study of postoperative RT field size, the VORTEX study, is in progress in the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/130\">",
"     130",
"    </a>",
"    ]. In this study, patients are randomized to either an initial larger clinical target volume extending 5 cm proximally and distally on the tumor bed or 1 cm beyond the scar, whichever is longer in the cranio-caudal direction and minimum margin of 2 cm axially to 50 Gy followed by a reduced field with 2 cm craniocaudal margin on the tumor bed GTV and minimum margin of 2 cm axially for another 16 Gy or to the single reduced field for the entire 66 Gy.",
"   </p>",
"   <p>",
"    For treatment of an extremity lesion, a good functional result demands that only a portion of the cross section of the extremity be irradiated to any significant dose level. Thus, some tissue should be spared from high doses to provide for lymphatic drainage. For large tumors that have been treated with wide resection, there may be persistent leg edema, requiring the use of a pressure-type stocking, even though the radiation treatment volume was less than circumferential. This is generally only a problem for patients with large (&gt;10 cm) sarcomas of the medial thigh.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Preoperative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients treated preoperatively, 50 Gy is administered in 25 fractions over five weeks followed three to four weeks later by a conservative resection. A boost dose to 66 Gy is given postoperatively or intraoperatively for microscopically positive margins and to 75 Gy if there is gross residual disease. In patients with frozen section evidence of close or positive margins, a boost can be delivered by placement of brachytherapy catheters or intraoperative electron beam radiation therapy.",
"   </p>",
"   <p>",
"    Intraoperative electron radiation doses of 10 to 15 Gy for microscopic residual disease (up to 12.5 Gy if the neurovascular bundle is in the field) can be delivered. Brachytherapy can be given by a low dose rate technique (16 Gy) or a high-dose rate approach (14 Gy in four twice daily fractions for microscopically positive margins and 25 Gy for gross residual tumor). If these techniques are not technically feasible, then a postoperative external beam RT boost can be used, generally delivering 16 to 18 Gy in fractionated treatment once the surgical wound has healed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Postoperative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients undergoing exclusively postoperative RT, treatment usually begins approximately three weeks following surgery once the surgical wound has healed. Following resection of large tumors, it may be necessary to wait three to four weeks to allow resorption of the seroma. The initial volume must include all tissues handled during the surgical procedure, including the drain site. The dose to the initial volume is 50 Gy and then through two subsequent treatment volumes the final dose is 60 Gy for negative margins, 66 to 68 Gy for positive margins or locally recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/131\">",
"     131",
"    </a>",
"    ], and 75 Gy for gross residual disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Newer techniques: IMRT and proton beam RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intent of RT is to achieve maximal dose to the tumor while minimizing the exposure of RT-sensitive critical structures to high RT doses. Traditionally, this has been achieved by shaping the spatial distribution of the dose to conform to the target volume (hence, 3D-CRT), thereby reducing the dose to the non-target structures. Although this approach is satisfactory for the treatment of targets that are roughly convex in shape, it is suboptimal for targets that contain complex concavities or that wrap around critical structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Growing experience suggests that the delivery of conformal RT using an intensity-modulated RT (IMRT) technique produces superior dose distributions than 3D-CRT plans, both in terms of dose conformity in the tumor and dose reduction to specified critical normal structures, albeit at the cost of some low-intermediate dose to some normal tissues that otherwise might not be irradiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32630?source=see_link\">",
"     \"Intensity-modulated radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IMRT treatment plans often have localized areas of dose inhomogeneity within the high-dose volume, where the received dose is from 10 to 15 percent above the target dose. Because there can also be areas of dose inhomogeneity to 5 percent below the target dose, treatment plans may be normalized to the 95 percent isodose line, meaning that selected areas of the treatment volume receive daily fractions and total doses of 15 to 20 percent above the target dose. Depending on the location of these \"hot spots\", there can be unanticipated acute normal tissue toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/134\">",
"     134",
"    </a>",
"    ]. Furthermore, because of the multiple field angles employed with IMRT, a larger fraction of the circumference of the extremity will be irradiated, albeit to lower dose (ie, more of the extremity will be exposed to some, relative lower RT dose).",
"   </p>",
"   <p>",
"    Whether there are late effects attributable to these focal areas of high dose or the higher integral dose remains to be seen. Initial results from this approach appear promising; the five-year actuarial local control rate was 94 percent in one series, and there was a favorable morbidity profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proton beam RT has been used to deliver highly conformal RT doses to sarcomas of the base of skull and spine, as well as pediatric rhabdomyosarcomas. While experience is limited, it may be helpful to manage selected patients with extremity soft tissue sarcomas such as those with large proximal thigh tumors and lesions closely approximated to joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/136\">",
"     136",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10968?source=see_link\">",
"     \"Proton and ion beams in cancer therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     POSTTREATMENT CANCER SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since isolated limited metastatic tumor to the lung can be resected and is frequently asymptomatic, we recommend frequent follow-up, particularly in the first two years after treatment, since more than 80 percent of recurrences will be detected during this period. One exception to this general rule is that synovial sarcomas tend to grow slowly, and they are associated with a high incidence of late metastases, even after 10 years. In one series, the mean metastasis-free survival was 11 years (range 0.5 to 28 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/137\">",
"     137",
"    </a>",
"    ]. Patients who experience a local recurrence of their tumor also appear to be at higher risk for late metastases, even if they are otherwise at low risk for metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Posttreatment cancer surveillance guidelines have not been established through rigorous clinical investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/139\">",
"     139",
"    </a>",
"    ].Consensus-based surveillance guidelines after treatment of an extremity sarcoma from NCCN include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/47/38650/abstract/98\">",
"     98",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I disease:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      History and physical examination every three to six months for two to three years, then annually.",
"     </li>",
"     <li>",
"      &ldquo;Consider&rdquo; chest imaging every 6 to 12 months.",
"     </li>",
"     <li>",
"      Periodic imaging of the primary site, based on estimated risk of locoregional recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage II and III:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      History and physical examination and chest imaging every three to six months for two to three years, then every six months for the next two years, then annually.",
"     </li>",
"     <li>",
"      Periodic imaging of the primary site, based on estimated risk of locoregional recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, we follow these guidelines.",
"   </p>",
"   <p>",
"    Imaging of the primary site can be accomplished using MRI or CT. For those patients at higher risk of local recurrence such as those with positive margins or those whose primary tumor site is not easily examined, we prefer MRI of the primary site over CT scans. We scan the primary site at four to six month intervals for the first two years and then yearly out to five years.",
"   </p>",
"   <p>",
"    When planning the posttreatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/26/16802?source=see_link\">",
"       \"Patient information: Soft tissue sarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue sarcomas (STS) are uncommon malignant tumors that arise from skeletal and extraskeletal connective tissues, including the peripheral nervous system. They can arise from mesenchymal tissue at any body site. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because of their rarity and the frequent need for multimodality treatment, evaluation and management of soft tissue sarcomas should ideally be carried out in a center with expertise in the treatment of sarcomas, including surgical, orthopedic, medical, pediatric, and radiation oncology. (See",
"    <a class=\"local\" href=\"#H7790646\">",
"     'Importance of multidisciplinary evaluation and management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In treating STS of the extremities and chest wall, the major therapeutic goals are survival, avoidance of a local recurrence, maximizing function, and minimizing morbidity. There are a wide variety of clinical situations that arise from involvement of a variety of different anatomic sites, the range of histologies, and variability in grade and tumor size. As a result, for most patients, treatment must be individualized. The following suggestions can serve as a useful guide to therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical resection of the primary tumor is the essential component of treatment for virtually all patients. The guiding principle is total en bloc excision of the primary tumor without cutting into tumor tissue. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most adult-type STS have a &le;5 percent risk of lymph node metastases, and surgical assessment of the regional nodes is unnecessary. The only exceptions are certain histologies (synovial sarcoma, the vascular sarcomas, rhabdomyosarcomas, and the epithelioid and clear cell subtypes), which have a higher risk of nodal metastases (11 to 44 percent). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management of the regional nodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combination of surgery and radiation therapy (RT) achieves better local control than either modality alone for the majority of STS for which adjuvant therapy is indicated (ie, high grade tumors &gt;5 cm where wide or radical margins are not possible short of amputation). In addition, the use of adjunctive RT maximizes functional outcomes while avoiding the significant morbidity and cosmetic deformity associated with radical resection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Benefit of RT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Limb salvage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, we reserve surgical excision alone for patients with superficial tumors that are low-grade and 5 cm or less in diameter, as well as carefully selected patients with small purely intramuscular tumors, even if higher grade, provided that adequate surgical margins can be obtained. The exact amount of normal tissue necessary for an \"adequate\" margin is not well defined and probably depends on the type of tissue. For example, a fascial margin can be thinner than a muscle or fatty margin. In addition, some low-grade, well-differentiated liposarcomas may be managed initially with surgery alone, even if &gt;5 cm and deep seated, if wide resection margins can be achieved, and the location is one where it might be possible to safely reresect a local recurrence ten or twenty years later. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Benefit of RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all other patients with intermediate-grade and high-grade STS, as well as those with larger, deep low-grade STS, we recommend the addition of RT to surgical excision to improve local control (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For &gt;5 cm, deep-seated intermediate or high-grade tumors of either the extremities or the chest wall, we suggest preoperative rather than postoperative RT (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Preoperative versus postoperative RT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For large, low-grade deep tumors where the surgeon expects close or positive margins, we prefer preoperative radiation. If the surgeon feels that adequate margins may be obtained, we prefer surgery initially, reserving the decision regarding radiation therapy until after review of the final pathology from the resection specimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with intermediate or high-grade STS larger than 8 cm in diameter, we suggest neoadjuvant therapy prior to resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The specific neoadjuvant approach (concurrent chemoradiotherapy with single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      or some other agent, interdigitated chemoradiotherapy, RT alone, or sequential chemotherapy followed by RT) depends upon institutional expertise and experience. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Initial chemoradiotherapy for large high-grade STS'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27354?source=see_link\">",
"       \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The benefit of adjuvant chemotherapy following optimal local therapy remains uncertain. This approach cannot be adopted as the standard of practice for all extremity soft tissue sarcomas. However, patients with high-risk tumors should be considered for clinical trials of adjuvant therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14521?source=see_link&amp;anchor=H2#H2\">",
"       \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\", section on 'Adjuvant chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with an incompletely resected primary STS, reresection is preferred, if possible. For patients who are not candidates for reresection, either because of a medical contraindication or the desire to preserve extremity function, RT can secure local control in a substantial proportion. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management of an initially incompletely resected primary tumor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are medically inoperable, or if a function-preserving resection is not possible and amputation is not accepted, RT alone is an effective treatment for STS. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'RT alone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following treatment, for patients with stage II or III disease, we suggest history and physical examination and chest imaging every three to six months for two to three years, then every six months for the next two years, then annually. Following treatment of stage I disease, we suggest a history and physical examination at three to six month intervals for the first two years, and yearly thereafter. Periodic imaging of the primary site is also indicated. For patients at higher risk of local recurrence such as those with positive margins or whose primary tumor site is not easily examined, MRI is preferred over CT scanning. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Posttreatment cancer surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/2\">",
"      Gustafson P, Dreinh&ouml;fer KE, Rydholm A. Soft tissue sarcoma should be treated at a tumor center. A comparison of quality of surgery in 375 patients. Acta Orthop Scand 1994; 65:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/3\">",
"      Tanabe KK, Pollock RE, Ellis LM, et al. Influence of surgical margins on outcome in patients with preoperatively irradiated extremity soft tissue sarcomas. Cancer 1994; 73:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/4\">",
"      Gortzak Y, Lockwood GA, Mahendra A, et al. Prediction of pathologic fracture risk of the femur after combined modality treatment of soft tissue sarcoma of the thigh. Cancer 2010; 116:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/5\">",
"      Brooks AD, Gold JS, Graham D, et al. Resection of the sciatic, peroneal, or tibial nerves: assessment of functional status. Ann Surg Oncol 2002; 9:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/6\">",
"      Ghert MA, Davis AM, Griffin AM, et al. The surgical and functional outcome of limb-salvage surgery with vascular reconstruction for soft tissue sarcoma of the extremity. Ann Surg Oncol 2005; 12:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/7\">",
"      Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982; 196:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/8\">",
"      Potter DA, Kinsella T, Glatstein E, et al. High-grade soft tissue sarcomas of the extremities. Cancer 1986; 58:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/9\">",
"      Wilson AN, Davis A, Bell RS, et al. Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer 1994; 30A:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/10\">",
"      Wanebo HJ, Temple WJ, Popp MB, et al. Preoperative regional therapy for extremity sarcoma. A tricenter update. Cancer 1995; 75:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/11\">",
"      Mundt AJ, Awan A, Sibley GS, et al. Conservative surgery and adjuvant radiation therapy in the management of adult soft tissue sarcoma of the extremities: clinical and radiobiological results. Int J Radiat Oncol Biol Phys 1995; 32:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/12\">",
"      O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002; 359:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/13\">",
"      McGee L, Indelicato DJ, Dagan R, et al. Long-term results following postoperative radiotherapy for soft tissue sarcomas of the extremity. Int J Radiat Oncol Biol Phys 2012; 84:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/14\">",
"      Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996; 14:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/15\">",
"      Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998; 16:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/16\">",
"      Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996; 14:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/17\">",
"      Al-Refaie WB, Habermann EB, Jensen EH, et al. Surgery alone is adequate treatment for early stage soft tissue sarcoma of the extremity. Br J Surg 2010; 97:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/18\">",
"      Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002; 20:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/19\">",
"      Fleming JB, Cantor SB, Varma DG, et al. Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer 2001; 92:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/20\">",
"      Fleming JB, Berman RS, Cheng SC, et al. Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol 1999; 17:2772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/21\">",
"      Rydholm A. Surgery without radiotherapy in soft tissue sarcoma. Acta Orthop Scand Suppl 1997; 273:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/22\">",
"      Cahlon O, Brennan MF, Jia X, et al. A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation. Ann Surg 2012; 255:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/23\">",
"      Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992; 215:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/24\">",
"      LeVay J, O'Sullivan B, Catton C, et al. Outcome and prognostic factors in soft tissue sarcoma in the adult. Int J Radiat Oncol Biol Phys 1993; 27:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/25\">",
"      Manoso MW, Frassica DA, Deune EG, Frassica FJ. Outcomes of re-excision after unplanned excisions of soft-tissue sarcomas. J Surg Oncol 2005; 91:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/26\">",
"      McNeer GP, Cantin J, Chu F, Nickson JJ. Effectiveness of radiation therapy in the management of sarcoma of the soft somatic tissues. Cancer 1968; 22:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/27\">",
"      Canter RJ, Beal S, Borys D, et al. Interaction of histologic subtype and histologic grade in predicting survival for soft-tissue sarcomas. J Am Coll Surg 2010; 210:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/28\">",
"      Talbert ML, Zagars GK, Sherman NE, Romsdahl MM. Conservative surgery and radiation therapy for soft tissue sarcoma of the wrist, hand, ankle, and foot. Cancer 1990; 66:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/29\">",
"      Johnstone PA, Wexler LH, Venzon DJ, et al. Sarcomas of the hand and foot: analysis of local control and functional result with combined modality therapy in extremity preservation. Int J Radiat Oncol Biol Phys 1994; 29:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/30\">",
"      Karakousis CP, De Young C, Driscoll DL. Soft tissue sarcomas of the hand and foot: management and survival. Ann Surg Oncol 1998; 5:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/31\">",
"      Davis AM, Devlin M, Griffin AM, et al. Functional outcome in amputation versus limb sparing of patients with lower extremity sarcoma: a matched case-control study. Arch Phys Med Rehabil 1999; 80:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/32\">",
"      Robinson MH, Spruce L, Eeles R, et al. Limb function following conservation treatment of adult soft tissue sarcoma. Eur J Cancer 1991; 27:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/33\">",
"      Stinson SF, DeLaney TF, Greenberg J, et al. Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma. Int J Radiat Oncol Biol Phys 1991; 21:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/34\">",
"      Cribb GL, Loo SC, Dickinson I. Limb salvage for soft-tissue sarcomas of the foot and ankle. J Bone Joint Surg Br 2010; 92:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/35\">",
"      Davidge KM, Wunder J, Tomlinson G, et al. Function and health status outcomes following soft tissue reconstruction for limb preservation in extremity soft tissue sarcoma. Ann Surg Oncol 2010; 17:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/36\">",
"      Weddington WW Jr, Segraves KB, Simon MA. Psychological outcome of extremity sarcoma survivors undergoing amputation or limb salvage. J Clin Oncol 1985; 3:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/37\">",
"      Sugarbaker PH, Barofsky I, Rosenberg SA, Gianola FJ. Quality of life assessment of patients in extremity sarcoma clinical trials. Surgery 1982; 91:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/38\">",
"      Sadoski C, Suit HD, Rosenberg A, et al. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol 1993; 52:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/39\">",
"      Herbert SH, Corn BW, Solin LJ, et al. Limb-preserving treatment for soft tissue sarcomas of the extremities. The significance of surgical margins. Cancer 1993; 72:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/40\">",
"      Trovik CS, Bauer HC, Alveg&aring;rd TA, et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer 2000; 36:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/41\">",
"      Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003; 97:2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/42\">",
"      Gronchi A, Lo Vullo S, Colombo C, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg 2010; 251:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/43\">",
"      Al Yami A, Griffin AM, Ferguson PC, et al. Positive surgical margins in soft tissue sarcoma treated with preoperative radiation: is a postoperative boost necessary? Int J Radiat Oncol Biol Phys 2010; 77:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/44\">",
"      Verhey LJ. Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems. Semin Radiat Oncol 1999; 9:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/45\">",
"      Kepka L, Suit HD, Goldberg SI, et al. Results of radiation therapy performed after unplanned surgery (without re-excision) for soft tissue sarcomas. J Surg Oncol 2005; 92:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/46\">",
"      Eilber FR, Eckardt J. Surgical management of soft tissue sarcomas. Semin Oncol 1997; 24:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/47\">",
"      Kim B, Chen YL, Kirsch DG, et al. An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. Int J Radiat Oncol Biol Phys 2010; 77:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/48\">",
"      Ferguson PC, Griffin AM, O'Sullivan B, et al. Bone invasion in extremity soft-tissue sarcoma: impact on disease outcomes. Cancer 2006; 106:2692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/49\">",
"      Lin PP, Pino ED, Normand AN, et al. Periosteal margin in soft-tissue sarcoma. Cancer 2007; 109:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/50\">",
"      Behranwala KA, A'Hern R, Omar AM, Thomas JM. Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol 2004; 11:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/51\">",
"      Blazer DG 3rd, Lazar AJ, Xing Y, et al. Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry. Cancer 2009; 115:2971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/52\">",
"      Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993; 217:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/53\">",
"      Riad S, Griffin AM, Liberman B, et al. Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res 2004; :129.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer). Cancer Staging Manual, 7th edition, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.291.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/55\">",
"      Maduekwe UN, Hornicek FJ, Springfield DS, et al. Role of sentinel lymph node biopsy in the staging of synovial, epithelioid, and clear cell sarcomas. Ann Surg Oncol 2009; 16:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/56\">",
"      Tunn PU, Andreou D, Illing H, et al. Sentinel node biopsy in synovial sarcoma. Eur J Surg Oncol 2008; 34:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/57\">",
"      Seal A, Tse R, Wehrli B, et al. Sentinel node biopsy as an adjunct to limb salvage surgery for epithelioid sarcoma of the hand. World J Surg Oncol 2005; 3:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/58\">",
"      van Akkooi AC, Verhoef C, van Geel AN, et al. Sentinel node biopsy for clear cell sarcoma. Eur J Surg Oncol 2006; 32:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/59\">",
"      Fantini F, Monari P, Bassissi S, et al. Sentinel lymph node biopsy in clear cell sarcoma. J Eur Acad Dermatol Venereol 2007; 21:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/60\">",
"      Al-Refaie WB, Ali MW, Chu DZ, et al. Clear cell sarcoma in the era of sentinel lymph node mapping. J Surg Oncol 2004; 87:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/61\">",
"      Zornig C, Peiper M, Schr&ouml;der S. Re-excision of soft tissue sarcoma after inadequate initial operation. Br J Surg 1995; 82:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/62\">",
"      Noria S, Davis A, Kandel R, et al. Residual disease following unplanned excision of soft-tissue sarcoma of an extremity. J Bone Joint Surg Am 1996; 78:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/63\">",
"      Goodlad JR, Fletcher CD, Smith MA. Surgical resection of primary soft-tissue sarcoma. Incidence of residual tumour in 95 patients needing re-excision after local resection. J Bone Joint Surg Br 1996; 78:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/64\">",
"      Zagars GK, Ballo MT, Pisters PW, et al. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer 2003; 97:2544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/65\">",
"      Fiore M, Casali PG, Miceli R, et al. Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity. Ann Surg Oncol 2006; 13:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/66\">",
"      Funovics PT, Vaselic S, Panotopoulos J, et al. The impact of re-excision of inadequately resected soft tissue sarcomas on surgical therapy, results, and prognosis: A single institution experience with 682 patients. J Surg Oncol 2010; 102:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/67\">",
"      Alamanda VK, Crosby SN, Archer KR, et al. Primary excision compared with re-excision of extremity soft tissue sarcomas--is anything new? J Surg Oncol 2012; 105:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/68\">",
"      Rehders A, Stoecklein NH, Poremba C, et al. Reexcision of soft tissue sarcoma: sufficient local control but increased rate of metastasis. World J Surg 2009; 33:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/69\">",
"      Barkley HT Jr, Martin RG, Romsdahl MM, et al. Treatment of soft tissue sarcomas by preoperative irradiation and conservative surgical resection. Int J Radiat Oncol Biol Phys 1988; 14:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/70\">",
"      Brant TA, Parsons JT, Marcus RB Jr, et al. Preoperative irradiation for soft tissue sarcomas of the trunk and extremities in adults. Int J Radiat Oncol Biol Phys 1990; 19:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/71\">",
"      Bujko K, Suit HD, Springfield DS, Convery K. Wound healing after preoperative radiation for sarcoma of soft tissues. Surg Gynecol Obstet 1993; 176:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/72\">",
"      Cheng EY, Dusenbery KE, Winters MR, Thompson RC. Soft tissue sarcomas: preoperative versus postoperative radiotherapy. J Surg Oncol 1996; 61:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/73\">",
"      Kuklo TR, Temple HT, Owens BD, et al. Preoperative versus postoperative radiation therapy for soft-tissue sarcomas. Am J Orthop (Belle Mead NJ) 2005; 34:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/74\">",
"      Zagars GK, Ballo MT, Pisters PW, et al. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys 2003; 56:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/75\">",
"      Suit HD, Mankin HJ, Wood WC, Proppe KH. Preoperative, intraoperative, and postoperative radiation in the treatment of primary soft tissue sarcoma. Cancer 1985; 55:2659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/76\">",
"      O'Sullivan B, Davis AM, Turcotte R, et al. Five-year results of a randomized phase III trial of pre-operative vs. post-operative radiotherapy in extremity soft tissue sarcoma (abstract). Proc Am Soc Clin Oncol 2004; 23:815a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/77\">",
"      Davis AM, O'Sullivan B, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol 2005; 75:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/78\">",
"      Alektiar KM, Brennan MF, Singer S. Influence of site on the therapeutic ratio of adjuvant radiotherapy in soft-tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys 2005; 63:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/79\">",
"      Korah MP, Deyrup AT, Monson DK, et al. Anatomic tumor location influences the success of contemporary limb-sparing surgery and radiation among adults with soft tissue sarcomas of the extremities. Int J Radiat Oncol Biol Phys 2012; 82:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/80\">",
"      Alektiar KM, Zelefsky MJ, Brennan MF. Morbidity of adjuvant brachytherapy in soft tissue sarcoma of the extremity and superficial trunk. Int J Radiat Oncol Biol Phys 2000; 47:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/81\">",
"      Panchal JI, Agrawal RK, McLean NR, Dawes PJ. Early post-operative brachytherapy and free flap reconstruction in the management of sarcomas. Eur J Surg Oncol 1996; 22:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/82\">",
"      Alektiar KM, Brennan MF, Singer S. Local control comparison of adjuvant brachytherapy to intensity-modulated radiotherapy in primary high-grade sarcoma of the extremity. Cancer 2011; 117:3229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/83\">",
"      Kraybill WG, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol 2006; 24:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/84\">",
"      Kraybill WG, Harris J, Spiro IJ, et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer 2010; 116:4613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/85\">",
"      Tuma RS. Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst 2006; 98:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/86\">",
"      Canter RJ, Martinez SR, Tamurian RM, et al. Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma. Ann Surg Oncol 2010; 17:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/87\">",
"      Herrmann K, Benz MR, Czernin J, et al. 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res 2012; 18:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/88\">",
"      Benz MR, Czernin J, Allen-Auerbach MS, et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2009; 15:2856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/89\">",
"      Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, et al. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med 2010; 51:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/90\">",
"      Tateishi U, Kawai A, Chuman H, et al. PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study. Clin Nucl Med 2011; 36:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/91\">",
"      Tepper JE, Suit HD. Radiation therapy alone for sarcoma of soft tissue. Cancer 1985; 56:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/92\">",
"      Ruka W, Taghian A, Gioioso D, et al. Comparison between the in vitro intrinsic radiation sensitivity of human soft tissue sarcoma and breast cancer cell lines. J Surg Oncol 1996; 61:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/93\">",
"      Chung PW, Deheshi BM, Ferguson PC, et al. Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas. Cancer 2009; 115:3254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/94\">",
"      Todoroki T, Suit HD. Therapeutic advantage in preoperative single-dose radiation combined with conservative and radical surgery in different-size murine fibrosarcomas. J Surg Oncol 1985; 29:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/95\">",
"      Eilber FR, Eckardt JJ, Rosen G, et al. Neoadjuvant chemotherapy and radiotherapy in the multidisciplinary management of soft tissue sarcomas of the extremity. Surg Oncol Clin N Am 1993; 2:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/96\">",
"      Baldini EH, Goldberg J, Jenner C, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 1999; 17:3252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/97\">",
"      Pisters PW, Pollock RE, Lewis VO, et al. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg 2007; 246:675.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/99\">",
"      Shah AA, D'Amico TA. Primary chest wall tumors. J Am Coll Surg 2010; 210:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/100\">",
"      Salas S, Bui B, Stoeckle E, et al. Soft tissue sarcomas of the trunk wall (STS-TW): a study of 343 patients from the French Sarcoma Group (FSG) database. Ann Oncol 2009; 20:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/101\">",
"      Gross JL, Younes RN, Haddad FJ, et al. Soft-tissue sarcomas of the chest wall: prognostic factors. Chest 2005; 127:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/102\">",
"      Greager JA, Patel MK, Briele HA, et al. Soft tissue sarcomas of the adult thoracic wall. Cancer 1987; 59:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/103\">",
"      Gordon MS, Hajdu SI, Bains MS, Burt ME. Soft tissue sarcomas of the chest wall. Results of surgical resection. J Thorac Cardiovasc Surg 1991; 101:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/104\">",
"      Wouters MW, van Geel AN, Nieuwenhuis L, et al. Outcome after surgical resections of recurrent chest wall sarcomas. J Clin Oncol 2008; 26:5113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/105\">",
"      Tsukushi S, Nishida Y, Sugiura H, et al. Soft tissue sarcomas of the chest wall. J Thorac Oncol 2009; 4:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/106\">",
"      Cannon CP, Ballo MT, Zagars GK, et al. Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas. Cancer 2006; 107:2455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/107\">",
"      Peat BG, Bell RS, Davis A, et al. Wound-healing complications after soft-tissue sarcoma surgery. Plast Reconstr Surg 1994; 93:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/108\">",
"      Tseng JF, Ballo MT, Langstein HN, et al. The effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas. Ann Surg Oncol 2006; 13:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/109\">",
"      Davis AM, O'Sullivan B, Bell RS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 2002; 20:4472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/110\">",
"      Baldini EH, Lapidus MR, Wang Q, et al. Predictors for major wound complications following preoperative radiotherapy and surgery for soft-tissue sarcoma of the extremities and trunk: importance of tumor proximity to skin surface. Ann Surg Oncol 2013; 20:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/111\">",
"      Arbeit JM, Hilaris BS, Brennan MF. Wound complications in the multimodality treatment of extremity and superficial truncal sarcomas. J Clin Oncol 1987; 5:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/112\">",
"      Rosenberg LA, Esther RJ, Erfanian K, et al. Wound complications in preoperatively irradiated soft-tissue sarcomas of the extremities. Int J Radiat Oncol Biol Phys 2013; 85:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/113\">",
"      Lee HY, Cordeiro PG, Mehrara BJ, et al. Reconstruction after soft tissue sarcoma resection in the setting of brachytherapy: a 10-year experience. Ann Plast Surg 2004; 52:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/114\">",
"      Parker MJ, Livingstone V, Clifton R, McKee A. Closed suction surgical wound drainage after orthopaedic surgery. Cochrane Database Syst Rev 2007; :CD001825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/115\">",
"      Siegel HJ, Long JL, Watson KM, Fiveash JB. Vacuum-assisted closure for radiation-associated wound complications. J Surg Oncol 2007; 96:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/116\">",
"      Bickels J, Kollender Y, Wittig JC, et al. Vacuum-assisted wound closure after resection of musculoskeletal tumors. Clin Orthop Relat Res 2005; 441:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/117\">",
"      Delman KA, Johnstone PA. Vacuum-assisted closure for surgical wounds in sarcoma. J Surg Oncol 2007; 96:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/118\">",
"      Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006; 107:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/119\">",
"      Lahat G, Dhuka AR, Lahat S, et al. Complete soft tissue sarcoma resection is a viable treatment option for select elderly patients. Ann Surg Oncol 2009; 16:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/120\">",
"      Al-Refaie WB, Habermann EB, Dudeja V, et al. Extremity soft tissue sarcoma care in the elderly: insights into the generalizability of NCI Cancer Trials. Ann Surg Oncol 2010; 17:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/121\">",
"      Farshadpour F, Schaapveld M, Suurmeijer AJ, et al. Soft tissue sarcoma: why not treated? Crit Rev Oncol Hematol 2005; 54:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/122\">",
"      Biau DJ, Ferguson PC, Turcotte RE, et al. Adverse effect of older age on the recurrence of soft tissue sarcoma of the extremities and trunk. J Clin Oncol 2011; 29:4029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/123\">",
"      Mariani L, Miceli R, Kattan MW, et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 2005; 103:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/124\">",
"      Dalal KM, Kattan MW, Antonescu CR, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg 2006; 244:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/125\">",
"      Sampo M, Tarkkanen M, Tukiainen E, et al. A web-based prognostic tool for extremity and trunk wall soft tissue sarcomas and its external validation. Br J Cancer 2012; 106:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/126\">",
"      Niewald M, Berberich W, Schnabel K, et al. [A simple method for positioning and fixing the extremities during the radiotherapy of soft-tissue sarcomas]. Strahlenther Onkol 1990; 166:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/127\">",
"      Robinson MH, Bidmead AM, Harmer CL. Value of conformal planning in the radiotherapy of soft tissue sarcoma. Clin Oncol (R Coll Radiol) 1992; 4:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/128\">",
"      Kooy HM, van Herk M, Barnes PD, et al. Image fusion for stereotactic radiotherapy and radiosurgery treatment planning. Int J Radiat Oncol Biol Phys 1994; 28:1229.",
"     </a>",
"    </li>",
"    <li>",
"     Information on RTOG protocol 0630 is available online at www.clinicaltrials.gov/ct2/show/NCT00589121?term=RTOG+0630&amp;rank=1 (Accessed on April 01, 2011).",
"    </li>",
"    <li>",
"     Information on the VORTEX study is available online at file://clinicaltrials.gov/ct2/show/NCT00423618 (Accessed on April 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/131\">",
"      Zagars GK, Ballo MT. Significance of dose in postoperative radiotherapy for soft tissue sarcoma. Int J Radiat Oncol Biol Phys 2003; 56:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/132\">",
"      Chan MF, Chui CS, Schupak K, et al. The treatment of large extraskeletal chondrosarcoma of the leg: comparison of IMRT and conformal radiotherapy techniques. J Appl Clin Med Phys 2001; 2:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/133\">",
"      Hong L, Alektiar KM, Hunt M, et al. Intensity-modulated radiotherapy for soft tissue sarcoma of the thigh. Int J Radiat Oncol Biol Phys 2004; 59:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/134\">",
"      Lee N, Chuang C, Quivey JM, et al. Skin toxicity due to intensity-modulated radiotherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 2002; 53:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/135\">",
"      Alektiar KM, Brennan MF, Healey JH, Singer S. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J Clin Oncol 2008; 26:3440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/136\">",
"      Levin WP, Kooy H, Loeffler JS, DeLaney TF. Proton beam therapy. Br J Cancer 2005; 93:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/137\">",
"      Krieg AH, Hefti F, Speth BM, et al. Synovial sarcomas usually metastasize after &gt;5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors. Ann Oncol 2011; 22:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/138\">",
"      Trovik CS, Bauer HC. Local recurrence of soft tissue sarcoma a risk factor for late metastases. 379 patients followed for 0.5-20 years. Acta Orthop Scand 1994; 65:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/47/38650/abstract/139\">",
"      Patel SR, Zagars GK, Pisters PW. The follow-up of adult soft-tissue sarcomas. Semin Oncol 2003; 30:413.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7734 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38650=[""].join("\n");
var outline_f37_47_38650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7790646\">",
"      IMPORTANCE OF MULTIDISCIPLINARY EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXTREMITY SARCOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Benefit of RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Limb salvage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Functional outcome: limb salvage versus amputation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Importance of margins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Management of the regional nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Management of an initially incompletely resected primary tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Preoperative versus postoperative RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Initial chemoradiotherapy for large high-grade STS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RT alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - NCCN guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CHEST WALL SARCOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      WOUND HEALING AFTER SURGERY AND RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Timing of RT and wound complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Brachytherapy and wound complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Strategies to reduce wound morbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Tumor size, grade, and histologic subtype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22265690\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      RADIATION TREATMENT PLANNING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Clinical target volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Preoperative treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Postoperative treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Newer techniques: IMRT and proton beam RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      POSTTREATMENT CANCER SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7734\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7734|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/37/4703\" title=\"figure 1\">",
"      Postop nomogram sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7734|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/41/6812\" title=\"table 1\">",
"      Local failure STS post surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/13/23773\" title=\"table 2\">",
"      2010 TNM staging STS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/21/21854\" title=\"table 3\">",
"      Combination chemotherapy STS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/48/42764\" title=\"table 4\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/30/10733\" title=\"table 5\">",
"      2002 AJCC staging of STS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14521?source=related_link\">",
"      Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27689?source=related_link\">",
"      Breast sarcoma: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=related_link\">",
"      Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32551?source=related_link\">",
"      Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/26/16802?source=related_link\">",
"      Patient information: Soft tissue sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10968?source=related_link\">",
"      Proton and ion beams in cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27354?source=related_link\">",
"      Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_47_38651="Causes thyroid nodules PI";
var content_f37_47_38651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F51803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F51803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of thyroid nodules",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Benign",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Multinodular (sporadic) goiter (\"colloid adenoma\")",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hashimoto's (chronic lymphocytic) thyroiditis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cysts: colloid, simple, or hemorrhagic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Follicular adenomas",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Macrofollicular adenomas",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Microfollicular or cellular adenomas",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Hurthle-cell (oxyphil-cell) adenomas",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Macro- or microfollicular patterns",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Malignant",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Papillary carcinoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Follicular carcinoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Minimally or widely invasive",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Oxyphilic (Hurthle-cell) type",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Medullary carcinoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anaplastic carcinoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Primary thyroid lymphoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Metastatic carcinoma (breast, renal cell, others)",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38651=[""].join("\n");
var outline_f37_47_38651=null;
var title_f37_47_38652="ACC AHA angio periop evaluation";
var content_f37_47_38652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Preoperative Coronary Revascularization with either CABG or PCI",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that coronary revascularization should be performed with in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; A patient with stable angina and a significant left main coronary artery stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; A patient with stable angina and significant three vessel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; A patient with stable angina and significant two vessel disease with a significant proximal left anterior descending stenosis and either a left ventricular ejection fraction &lt;50 percent or demonstrable ischemia on noninvasive testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; A patient with high risk unstable angina, NSTEMI or STEMI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of benefit from coronary revascularization in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; A patient with angina not controlled with medical therapy who needs elective surgery in the next 12 months. In this setting balloon angioplasty or placement of a bare metal stent followed by dual antiplatelet therapy for four to six weeks is probably indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; For patients with drug-eluting stents who must discontinue thieonpyridine therapy due to urgent surgery, it is reasonable to continue aspirin and restart the thienopyridine as soon as possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for coronary revasuclarizaiton in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; A high-risk ischemic patient (eg, abnormal dobutamine stress echocardiogram with at least five segments of wall-motion abnormalities)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; A low risk ischemic patient with one to four abnormal segments on dobutamine stress-echocardiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that coronary angiography is not useful in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; A patient stable CAD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Elective non-cardiac surgery should not be performed within four to six weeks of coronary revascularization with a bare metal stent or within 12 months of a drug eluting stent in whom either thienopyridine therapy of both aspirin and thienopyridine therapy will need to be discontinued perioperatively",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Elective non-cardiac surgery should not be performed within four weeks of coronary revascularization with balloon angioplasty",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 2007; 50:e159.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38652=[""].join("\n");
var outline_f37_47_38652=null;
var title_f37_47_38653="Contents: Primary care calculators";
var content_f37_47_38653=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/20/19776\">",
"           Calculator: Alcohol consumption screening AUDIT questionnaire (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/0/33796\">",
"           Calculator: CIWA-Ar Clinical Institute Withdrawal Assessment for Alcohol scale",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/3/41023\">",
"           Calculator: International Prostatism Symptom Score (IPSS)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/26/29089\">",
"           Calculator: Lean body weight (adult female)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/21/29009\">",
"           Calculator: Lean body weight (adult male)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/55/36722\">",
"           Calculator: Post Test Probability from Pre Test Probability, Sensitivity and Specificity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/3/10291\">",
"           Calculator: Post-test probability from likelihood ratios and multiple test results",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/24/19841\">",
"           Calculator: SI unit conversions for immunology lab values",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-8781EF3881-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f37_47_38653=[""].join("\n");
var outline_f37_47_38653=null;
var title_f37_47_38654="Osteosarcoma in Paget";
var content_f37_47_38654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paget osteosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral radiograph in a patient with known Paget disease shows osteosarcoma arising in a pagetic area of the distal right femur. There is soft tissue swelling and destruction of the distal femoral cortex (arrows). Marked trabecular thickening consistent with Paget disease is also seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38654=[""].join("\n");
var outline_f37_47_38654=null;
var title_f37_47_38655="Med bronchogenic cyst MRI";
var content_f37_47_38655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paratracheal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An axial T2-weighted spin echo MR scan shows high signal in the right paratracheal mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_47_38655=[""].join("\n");
var outline_f37_47_38655=null;
